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Systemic lupus erythematosus (SLE) is an incurable autoimmune disease 
characterized by a wide array of clinical manifestations and involvement of multiple 
organs, such as skin, kidneys, and the central nervous system 1. Despite genetic 
susceptibility, the actual pathogenesis of SLE remains elusive 2. To note, SLE is a 
systemic autoimmune disease and it differs from other autoimmune diseases in 
such a way that no particular cell type seems to be targeted rather, the response 
seems to be directed against antigens that are widely expressed 3. Among these 
antigens, nuclear components (DNA, histones, ribonucleoproteins) are the major 
targets 1,3. Dying cells serve as potential reservoirs of modified forms of 
autoantigens that may trigger autoantibody responses in susceptible individuals 4. 
Therefore, it has been proposed that defective clearance of dying cells breaks
peripheral tolerance and predisposes to the development of SLE 5-7. Several in 
vitro and in vivo studies have provided evidence for a link between inappropriate 
clearance of dying cells and SLE 8,9. However, it remains unclear how apoptotic 
cell clearance is regulated by different phagocytes and soluble factors from the 
innate immune system, and how dying cells ultimately initiate a break of peripheral 
tolerance. 
2. The many modes of cell death
Cell death is an essential and highly orchestrated process, which contributes 
significantly to normal homeostasis and tissue turnover. There are at least three 
major modes of cell death: apoptosis, necrosis and autophagy 10. Apoptosis, 
coined in 1972 by Kerr et al. 11, comes from two Greek words, apo- and -ptosis. 
“Apo" means "separate from" and "ptosis" means "fall from"--a description of cells 
that naturally die as part of normal development without any inflammatory flare 
(cited from Wikipedia). Apoptosis is an active molecular “programmed” process 12-14. 
It was called “programmed”, owing to the significant findings by Sulston and Horvitz 
who elegantly showed that in each worm (C. elegans), out of 1090 newborn cells, 
the same 131 cells die during development, resulting in a nematode of exact 959 
cells 15. During apoptosis, dramatic biochemical and morphological changes take 
place, including the redistribution of membrane lipids such as phosphatidylserine 
(PS), and fragmentation of the nucleus 16. Importantly, the membrane of apoptotic 
cells remains intact until relatively late in the process 12. Thus based on the 
permeability of cell membranes, apoptotic cells can be further divided into two 
categories, namely early apoptotic and late apoptotic cells. 
In contrast to apoptosis, necrosis refers to a distinct mode of death where a cell 
swells and ruptures during its accidental demise 10, and that sometimes occurs as 
an alternative form of programmed cell death when apoptosis is blocked 17. To note, 
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late apoptotic cells are sometimes referred as post-apoptotic or secondary necrotic 
cells, behaving like necrotic cells as both of them release intracellular contents 18. 
In experimental settings, difference between apoptosis and necrosis can be 
appreciated at the changes of their sizes and granularities based on the dot plots 
of forward and side scatter by flow cytometry (Fig. 1).
Viable Early apoptotic Late apoptotic Necrotic
Figure 1. Distinct characteristics of cells at different stages of cell death. Jurkat T cells were 
treated with UV-C at a dose of 50J/m2, and cultured in serum-free RPMI culture medium for 3 
hours or 30 hours to obtain early apoptotic cells and late apoptotic cells, respectively. Necrosis was 
induced by incubating cells at 56°C for 1 hour. 
As a third major form of cell death, autophagy is a relatively new term and it is a 
process that a cell recycles cellular products such as cytoplasma and defective 
organelles 19. The major difference between apoptosis and autophagy is that 
apopotic cells are degraded by phagocytic cell lysosomes while autophagic cells do 
it by their endogeneous lysosomal machinery. It remains unclear whether 
























Figure 2. A brief history of apoptosis.
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3. The clearance machinery
The theory of “phagocytosis” was formulated by the pioneering biologist Elie 
Metchnikov in 1880’s, who won a Nobel Prize in 1908 (www.nobelprizes.com).
Phagocytosis was initially recognized as the first line of internal defence when 
foreign particles that enter our bodies. Although apoptosis or programmed cell 
death was discovered in 1960’s, not much attention has been paid by scientists to 
unravel the mechanisms of phagocytosis of apoptotic cells until the 1990’s 5,6,20,21
(Fig. 2). 
Investigators in the last 15 years have made clear that once a cell undergoes 
apoptosis, phosphatidyserine (PS) is redistributed onto the outer layer of the cell 
membrane and serves as the very first “eat me” signal to attract phagocytes and 
initiation of phagocytosis (Fig.3). There are many cell types that can be involved in 
the phagocytic process, including professional phagocytes, i.e. immature dendritic 
cells (iDCs) and macrophages (M), but also non-professional phagocytes, i.e. 
epithelial cells, fibroblasts or mesangial cells 22.  Even within the family of 
professional phagocytes, both DCs and M consist of heterogeneous subsets of 
cells with different functional characteristics 23,24. Therefore, the nature of a 
phagocyte defines the complexity and the consequence of phagocytosis. 
Furthermore, since both DCs and M are professional antigen presenting cells 
(APCs), processing of self-antigens derived from dying cells by these cells 






Figure 3. Recognition of apoptotic cells by phagocytes. Viable cells provide “don’t eat me”
signals, therefore are not recognized by phagocytes. Once cells undergo apoptosis, 
phosphatidyserine (PS) is redistributed onto the outer layer of the cell membrane, which then serve
as “eat me” signals. Phagocytes such as DCs and M are recruited by chemotactic stimuli to 
phagocytose the dying cells.
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4. Linking cell death to autoimmune lupus
Apoptotic cells are a rich source of autoantigens 25. During daily life, billions of cells 
undergo apoptosis and then are promptly phagocytosed by different phagocytes 
and/or APCs and the self-antigens are processed by these APCs or transferred to 
other professional APCs. Therefore, it is generally thought that presentation of 
antigens derived from apoptotic cells will contribute to the induction and
maintenance of peripheral tolerance or autoimmunity 5,6. Emerging evidence 
indicates that the uptake of apoptotic cells is immunosuppressive, as documented
by the fact that anti-inflammatory cytokines such as TGF- are induced whereas 
pro-inflammatory cytokines are inhibited, by phagocytes that have ingested 
apoptotic cells 26-29. This contrasts with the effect of late apoptotic or necrotic cell 
uptake, which leads to the activation of phagocytes and release of pro-
inflammatory cytokines 30,31. This is most likely due to “danger signals” such as 
heat shock proteins 32, HMGB1 33 and uric acid 34, that are released by necrotic 
cells. Each of these mediators is essential to induce DC maturation and activation 
of the immune system.
Another challenging recent view proposes that also stimuli for induction of 
apoptosis may define the immune response upon uptake by phagocytes 35. Several 
studies have shown that apoptosis triggered via death receptors results in release
of bio-active lipids such as sphingosine-1-phosphate (S1P) 36, or 
lysophosphatidylcholine (LPC) 37, which then signal through endothelial-derived G-
protein-coupled (EDG) receptors. As a consequence, EDG receptors activate
nuclear factor-B (NF-B), leading to a pro-inflammatory response 35. 
A central question is then how apoptotic /necrotic cells ultimately lead to aberrant 
autoimmunity?  The very first evidence from animal studies has shown that 
injection of large amounts of apoptotic cells into mice 38 or rats 39 led to the 
production of autoantibodies. In SLE patients, a decreased clearance of apoptotic 
cells has been documented 9,40, suggesting a strong link of defective clearance to 
autoimmunity. Furthermore, elevated levels of apoptotic cells have been found in 
the peripheral blood of SLE patients 41,42. Together, there is a prevailing belief that 
delayed or defective clearance of apoptotic cells ultimately leads to a break in self-
tolerance and induction of autoimmunity 5,9. 
During phagocytosis, soluble factors from the innate immune system enhance the 
interaction between dying cells and phagocytes and play an important role in this 
process. Both complement and other innate molecules such as pentraxin family 
members can opsonize apoptotic cells, and thereby promote their removal by 
phagocytes 16,43. In humans, homozygous deficiency of any of the early 
components of the classical pathway of complement (C1q, C1r, C1s, C4, and C2) 
predispose to the development of SLE 43, implying that complement is involved in 
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removal of dying cells. These observations are also supported by animal models 
showing that C1q knockout mice on certain genetic background develop lupus like 
disease and exhibit accumulation of apoptotic bodies in the glomeruli 8. 
Complement-mediated clearance of apoptotic cells has been well documented both 
in vitro 44 and in vivo 45. Activation of complement by the classical pathway (via C1q) 
and lectin pathway (via MBL and ficolin) on dying cells seems to be a favorable 
process 44-48, although complement activation may cause tissue damage and 
inflammation, suggesting that a balance between the two processes is desirable. 
Nevertheless, the main product of complement activation, iC3b, was suggested not 
only to facilitate the removal of dead material, but also to mediate peripheral 
tolerance 44,49,50.
Therefore, clearance of apoptotic cells is a complex process, involving many 
factors as discussed so far. Firstly, death stimuli may be important to determine 
which signal is going to be delivered to phagocytes. Secondly, appropriate 
opsonization by soluble factors from the innate immune system contributes
enormously to the removal of dying cells and the subsequent consequence on the 
immune response. Thirdly, as discussed earlier, the phagocyte system is largely 
heterogeneous, therefore the nature of a specific phagocyte that encounters a 
dying cell, defines the consequences of being eaten. In conclusion, the link 
between defective clearance of dying cells and autoimmune lupus has a 
reasonable solid scientific basis, but the exact immunological mechanisms involved 
remain to be defined. 
5. Scope of this thesis
The current thesis was dedicated to understand how different components of the 
innate immune system contribute to the clearance of apoptotic cells and to the 
immunological response involved in this process. In part I of this thesis, we focus
on the biology of phagocyte subsets and their role in the handling of dying cells.
This part consists of 4 chapters: Chapter 2 is a review discussing the latest 
knowledge on how different subsets of DCs and M handle dying cells, and 
particularly the immune response evoked by APCs that have eaten dying cells.  
Chapter 3 describes the differential contribution of pro-inflammatory M (GM-CSF-
driven M1) and anti-inflammatory M (M-CSF-driven M2) in the phagocytosis of 
early apoptotic, late apoptotic and necrotic cells and the mechanisms that are 
involved in this process. Chapter 4 is a follow-up of Chapter 3, describing the
finding that in vitro-polarized pro-inflammatory and anti-inflammatory M seem to 
have an in vivo counterpart as well. We analyzed human peritoneal M (pM) 
freshly isolated from patients on peritoneal dialysis and performed functional
comparisons among pM, M1 and M2. In Chapter 5, it is demonstrated that 
polarized pro-inflammatory and anti-inflammatory M can be re-differentiated 
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towards anti-inflammatory and pro-inflammatory cells by switching lineage-
determining factors GM-CSF and M-CSF, respectively.
In the latter part of this thesis (Part II), the role of serum factors in the handling of 
dying cells and its association to pathogenesis of SLE are described. Chapter 6
discusses the importance of the innate immune system, particularly complement, in 
the clearance of apoptotic cells. Chapter 7 reports on the role of properdin (an 
important positive complement regulator) on binding to dying cells and 
physiological consequences such as complement activation and immune regulation
by DCs and M. 
Finally, in Chapter 8 general conclusions are drawn and topics of interest are 
discussed. We also describe several ongoing studies in the direction of: 1.) 
elucidation of the role of serum factors in the processing of dying cells in SLE 
patients; 2.) dissection of how DCs, that are loaded with early, late or necrotic cells,
process and present antigens to T cells; 3.) immuno-modulation of M subsets.
Reference List
1 Kotzin BL. Systemic lupus erythematosus. Cell. 1996;85:303-306.
2 Vyse TJ, Kotzin BL. Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol. 
1998;16:261-292.
3 Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med. 
2001;7:899-905.
4 Huggins ML, Todd I, Cavers MA et al. Antibodies from systemic lupus erythematosus (SLE) sera 
define differential release of autoantigens from cell lines undergoing apoptosis. Clin Exp 
Immunol. 1999;118:322-328.
5 Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784-
788.
6 Henson PM, Bratton DL, Fadok VA. Apoptotic cell removal. Curr Biol. 2001;11:R795-R805.
7 Carroll MC. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev 
Immunol. 2004;4:825-831.
8 Botto M, Dell'Agnola C, Bygrave AE et al. Homozygous C1q deficiency causes 
glomerulonephritis associated with multiple apoptotic bodies [see comments]. Nat Genet. 
1998;19:56-59.
9 Baumann I, Kolowos W, Voll RE et al. Impaired uptake of apoptotic cells into tingible body 




10 Nelson DA, White E. Exploiting different ways to die. Genes Dev. 2004;18:1223-1226.
11 Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging 
implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
12 Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 
1995;146:3-15.
13 Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-776.
14 Green DR. Apoptotic pathways: ten minutes to dead. Cell. 2005;121:671-674.
15 Sulston JE, Horvitz HR. Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. 
Dev Biol. 1977;56:110-156.
16 Nauta AJ, Daha MR, Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for 
complement and pentraxins. Trends Immunol. 2003;24:148-154.
17 Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell 
death? Exp Cell Res. 2003;283:1-16.
18 Wu X, Molinaro C, Johnson N, Casiano CA. Secondary necrosis is a source of proteolytically 
modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. 
Arthritis Rheum. 2001;44:2642-2652.
19 Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 
2004;306:990-995.
20 Haslett C, Savill JS, Whyte MK et al. Granulocyte apoptosis and the control of inflammation. 
Philos Trans R Soc Lond B Biol Sci. 1994;345:327-333.
21 Savill J. Recognition and phagocytosis of cells undergoing apoptosis. Br Med Bull. 1997;53:491-
508.
22 Ren Y, Savill J. Apoptosis: the importance of being eaten. Cell Death Differ. 1998;5:563-568.
23 Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. 
Cell. 2001;106:259-262.
24 Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23-35.
25 Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus 
are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 
1994;179:1317-1330.
26 Fadok VA, Bratton DL, Konowal A et al. Macrophages that have ingested apoptotic cells in vitro 
inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving 
TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101:890-898.




28 Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that 
have captured apoptotic cells. J Exp Med. 2000;191:411-416.
29 Kim S, Elkon KB, Ma X. Transcriptional suppression of interleukin-12 gene expression following 
phagocytosis of apoptotic cells. Immunity. 2004;21:643-653.
30 Ip WK, Lau YL. Distinct maturation of, but not migration between, human monocyte-derived 
dendritic cells upon ingestion of apoptotic cells of early or late phases. J Immunol. 
2004;173:189-196.
31 Sauter B, Albert ML, Francisco L et al. Consequences of cell death: exposure to necrotic tumor 
cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory 
dendritic cells. J Exp Med. 2000;191:423-434.
32 Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol. 
2000;1:151-155.
33 Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers 
inflammation. Nature. 2002;418:191-195.
34 Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune 
system to dying cells. Nature. 2003;425:516-521.
35 Albert ML. Death-defying immunity: do apoptotic cells influence antigen processing and 
presentation? Nat Rev Immunol. 2004;4:223-231.
36 Lee MJ, Van Brocklyn JR, Thangada S et al. Sphingosine-1-phosphate as a ligand for the G 
protein-coupled receptor EDG-1. Science. 1998;279:1552-1555.
37 Lauber K, Bohn E, Krober SM et al. Apoptotic cells induce migration of phagocytes via caspase-
3-mediated release of a lipid attraction signal. Cell. 2003;113:717-730.
38 Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells 
induces autoantibody production. J Exp Med. 1998;188:387-392.
39 Patry YC, Trewick DC, Gregoire M et al. Rats injected with syngenic rat apoptotic neutrophils 
develop antineutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2001;12:1764-1768.
40 Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG. Reduced uptake of apoptotic cells by 
macrophages in systemic lupus erythematosus: correlates with decreased serum levels of 
complement. Ann Rheum Dis. 2006;65:57-63.
41 Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M. High levels of circulating early 
apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus. 
1998;7:113-118.
42 Courtney PA, Crockard AD, Williamson K et al. Increased apoptotic peripheral blood neutrophils 
in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded 
DNA, and neutropenia. Ann Rheum Dis. 1999;58:309-314.
Chapter 1
- 18 -
43 Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic 
lupus erythematosus. Annu Rev Immunol. 2004;22:431-456.
44 Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of 
apoptotic cells by human macrophages. J Exp Med. 1998;188:2313-2320.
45 Taylor PR, Carugati A, Fadok VA et al. A hierarchical role for classical pathway complement 
proteins in the clearance of apoptotic cells in vivo. J Exp Med. 2000;192:359-366.
46 Ogden CA, deCathelineau A, Hoffmann PR et al. C1q and mannose binding lectin engagement 
of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J 
Exp Med. 2001;194:781-795.
47 Nauta AJ, Castellano G, Xu W et al. Opsonization with C1q and mannose-binding lectin targets 
apoptotic cells to dendritic cells. J Immunol. 2004;173:3044-3050.
48 Jensen ML, Honore C, Hummelshoj T et al. Ficolin-2 recognizes DNA and participates in the 
clearance of dying host cells. Mol Immunol. 2007;44:856-865.
49 Verbovetski I, Bychkov H, Trahtemberg U et al. Opsonization of apoptotic cells by autologous 
iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-
regulates CC chemokine receptor 7. J Exp Med. 2002;196:1553-1561.
50 Sohn JH, Bora PS, Suk HJ et al. Tolerance is dependent on complement C3 fragment iC3b 
binding to antigen-presenting cells. Nat Med. 2003;9:206-212.
- 19 -
Dendritic cell and macrophage subsets in the handling
of dying cells
Wei Xu, Anja Roos, Mohamed R. Daha, and Cees van Kooten  
Department of Nephrology, Leiden University Medical Center, Leiden, the 
Netherlands
Summary
Dendritic cells and macrophages are major components of the phagocyte system 
and are professional antigen presenting cells. In the current review, we discuss the 
differential contribution of dendritic cell and macrophage subsets in the clearance 
of dying cells and the consequence of the process of these cells. We hypothesize 
that under steady-state conditions, the clearance of apoptotic cells is mostly 
confined to a specialized subset of phagocytes with anti-inflammatory properties. 




Phagocytes constantly remove excessive dying cells during normal homeostasis 
and tissue turnover. Since 1990, significant progress has been made in 
understanding the immunological meaning of clearance of dying cells 1-4. The 
underlying accepted paradigm is that apoptotic cells provide "eat me signals" to 
phagocytes to promptly and efficiently engulf apoptotic cells during the early stage 
of cell death, thus preventing them to release noxious substances in the local 
environment. In contrast, late apoptotic cells or necrotic cells might provide danger 
signals to activate antigen presenting cells (APCs), potentially breaking self-
tolerance 2,3. One of the well-established examples, both in mice 5,6 and men 7 of a 
disorder in which apoptotic cell clearance is disturbed is systemic lupus 
erythematosus (SLE) 8.
There are several checkpoints conceivable which together determine the 
immunological response towards the safe clearance of dying cells (Figure 1).  I.) 
The different modes of cell death might determine the fate of clearance. There are 
at least three major types of cell death: apoptosis, necrosis and autophagy 9, which 
exhibit distinct biochemical and morphological changes 9-11. Depending on the 
respective stimuli of death induction, these dying cells might determine phagocyte 
activation and antigen processing 12. II.) Opsonization of apoptotic cells by 
components of the innate immune system, such as complement factors and 
pentraxin family members, facilitates and modulates the clearance of apoptotic 
cells 13. III.) Finally, since the mononuclear phagocyte system is largely 
heterogeneous 14, the nature of phagocytes that phagocytose apoptotic cells might 
provide a defined immunological response (Fig. 1). 
The concept of differences of dying cells and the differential contribution of 
opsonins has been extensively reviewed 12,13,15-18. In the present review, we will 
concentrate on the differential contribution of phagocyte subsets, particularly 
subsets of dendritic cells (DCs) and macrophages (MØ) in the clearance of dying 
cells, as both cell types are professional phagocytes and APCs. Phagocyte subsets 
might be cells with intrinsic pro-inflammatory or anti-inflammatory characteristics. 
We suggest that the clearance of apoptotic cells is mostly confined to a specialized 
subset of phagocytes with anti-inflammatory properties.
DC subsets in the clearance of dying cells
DC subsets
Among the different phagocyte subsets, DCs are the most potent professional 
APCs 19. Being an important component of the innate immune system, DCs have 
been demonstrated in almost all peripheral organs and in lymphoid tissues 20. The 
heterogenity of DCs has been extensively studied. In mice, at least six DC subsets 
Dendritic cells and macrophages in the handling of dying cells
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have been described in lymph nodes, derived from two distinct pathways, myeloid 
and lymphoid 21. They are distinguished by surface markers such as CD11b, 














Figure 1. Three checkpoints determine the immunological response during clearance of 
dying cells. I.) The various modes of cell death such as apoptosis, (secondary) necrosis or 
autophagy, might determine the fate of dead cells. II.) Opsonization of apoptotic cells by 
components of the innate immune system, such as complement factors and pentraxin family 
members, facilitates and modulates the clearance of apoptotic cells. III.) The type of phagocytes 
that take up apoptotic cells might provide a defined immunological response.
In contrast to well-studied mouse DCs, human DCs have been studied to a 
relatively lesser degree. Blood is the only readily available source and at least 
three subtypes of blood-driven DCs have been characterized: Langerhans DCs 
(LDCs), interstitial DCs (iDCs) and plasmacytoid DCs (pDCs) 21. Most of the 
insights into human DC subsets are derived from in vitro studies, following the 
identification of DC precursors, i.e., CD34+ cells from umbilical cord blood or bone 
marrow, blood monocytes, and plasmacytoid precursors from blood. Migration into 
non-lymphoid organs, for example the interstitium of peripheral organs, induces 
differentiation of DC precursors into resident tissue DCs 22. One of the 
characteristics of resident DCs is that they are able to capture self (such as cellular 
debris) and foreign (such as microbial pathogens) antigens by several mechanisms 
20. The maturation status of DCs after antigen-capture determines whether they 
prime T cells or induce immune tolerance 23. Taken together, in vitro and in vivo




Clearance of dying cells by DCs
Although heterogeneous populations of DCs have been described in mice and 
humans (as discussed above), relatively few studies have addressed the question 
whether DC subsets contribute differentially to the uptake of dying cells. Most of 
the available studies have investigated dying cell clearance by DCs either using 
immature monocyte-derived DCs (iMoDCs) in humans 24-26 or splenic CD8+ DCs 
27,28 or BM CD11c+ DCs  29 in mice. These data show that DC subsets from 
different sources can phagocytose dying cells. However, it has been suggested 
that phagocytosis of dying cells by DCs is restricted to certain types of DCs. For 
example, although both CD8+ and CD8- DCs phagocytose latex particles in culture 
and both DC subsets present soluble ovalbumin captured in vivo, only CD8+ DC is 
specialized in the phagocytosis of dying cells 28. Another in vitro study compared 
the subsets of splenic CD8 DCs and found that splenic CD8+ DC are superior to 
other DC subsets in internalizing dying cells 30.
Also human DC subsets exhibit differential capacities to phagocytose dying cells. A 
recent study compared side-by-side the phagocytic capacity among three human 
DC subsets: CD11c+ DCs, iMoDCs and pDCs, and found that iMoDCs are three 
times better in the phagocytosis of apoptotic cells than CD11c+ DCs, whereas 
pDCs were hardly able to take up apoptotic cells 31. This suggests that the uptake 
of dead material is probably confined to myeloid subsets of DCs. 
Consequence of uptake by DCs
Apoptotic cells are a rich source of autoantigens 32. Upon uptake, DCs acquire 
antigens from apoptotic cells and (cross-)present these antigens to class I- or class 
II-restricted T cells 25,33,34. It remains controversial whether apoptotic cells indeed 
induce maturation of DCs and whether they stimulate or tolerize T cells. It has been 
shown that necrotic cells or late apoptotic cells, but not (early) apoptotic cells 
trigger DC maturation 35,36. However, others showed that bystander or excessive 
apoptotic cells induce maturation of DCs, and present antigens in the absence of 
exogenous danger signals 24,34. It should be realized that these studies have made 
use of different sources of DCs, including PBMC 35,36 or D1 cell lines 24,34. Similarly, 
various apoptotic targets are used in different studies, such as Jurkat T cells 36, 293 
cell lines 35 and OVA-RMA cells 24,34. Thus different cells used in the studies might 
explain the substantial difference in the consequence of uptake of apoptotic cells 
by DCs.
Whether uptake of apoptotic cells leads to DC activation in the context of pro- or
anti-inflammatory conditions is also depending on how the death stimuli are applied 
12. Several studies have shown that apoptosis triggered via death receptors could 
release bio-active lipids such as sphingosine-1-phosphate (S1P) 37, or 
Dendritic cells and macrophages in the handling of dying cells
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lysophosphatidylcholine (LPC) 38. These agents signal through endothelial-derived 
G-protein-coupled (EDG) receptors and these receptors are known to signal 
through nuclear factor-B (NF-B), leading to a pro-inflammatory response 12.
To validate the immune regulatory role of apoptotic cells, also in vivo studies have 
been performed. Mouse CD8+ DC were shown to actively capture apoptotic cells 
and induce immune tolerance 27,28. These findings are supported by another in vivo 
study showing that a subset of rat DCs, CD4-/OX41- DCs, constitutively 
endocytoses and transports apoptotic cells to the T cell areas of mesenteric lymph 
nodes 39, suggesting that DCs carrying apoptotic material can silence T cells 
against self-antigens 40. 
If under normal conditions, apoptotic cell removal by DCs is an immunologically 
silent process, the question remains how apoptotic cell-loaded DCs break 
peripheral tolerance, as observed in SLE. One possibility is that when early 
apoptotic cells are not removed promptly, the remaining cells might become late 
apoptotic (or secondary necrotic), thus converting immune tolerance to 
autoimmunity. In lupus-prone mice, only DCs loaded with necrotic cells, but not 
apoptotic cells, induce lupus-like disease 29, suggesting that the intracellular 
contents released from necrotic cells provide additional danger signals and lead to 
activation of DCs. A second possibility is that the presentation of autoantigens 
derived from apoptotic cells by DCs to T cells could be triggered by the presence of 
ligands for TLRs. A very recent paper showed that only DCs captured apoptotic 
cells in the presence of TLR4 triggering by LPS could present antigens to CD4 T 
cells and induce IL-2 production 41. However, simultaneous phagocytosis of
apoptotic cells and microbial pathogens does result in DC maturation, but under 
these conditions only antigens from bacteria, but not the ones from apoptotic cells, 
were presented to CD4 T cells 41. Thus extra danger signals provided by TLR 
ligands could make a substantial contribution in the initiation of autoimmunity by 
apoptotic cell-loaded DCs.
Another possible explanation could be that one specialized DC subset contributes 
exclusively to initiate autoimmunity. Recently, much attention has focused on 
understanding of how DNAs and RNAs containing autoantigens, that are derived 
from dying cells, activate DCs in the setting of SLE. Although a previous study 
showed that in vitro pDCs do not take up apoptotic cells 31, they do take up immune 
complexes (ICs) containing DNAs 42. It was shown that ICs derived from patients 
with SLE , upon intracellular delivery via CD32, were able to activate pDCs through 
toll like receptor 9 (TLR9) 42. This observation was extended in another study 
showing that small nuclear RNAs within ribonucleoprotein particles activate pDCs 
through TLR7 43, suggesting a link between pDCs and autoimmmunity to both 
DNA- and RNA-containing autoantigens. These data have provided novel insights 
in the mechanisms of loss of peripheral tolerance to autoantigens in SLE. The 
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suggestion that SLE is a pDC-driven disease seems to be confirmed by the 
identification of IFN- as an important pathogenic factor 44,45. 
MØ subsets in the clearance of dying cells
MØ subsets
It has been proposed that at least two types of MØ exist in vivo: resident (tissue) 
MØ and inflammatory elicited MØ 46. Most resident MØ are derived from circulating 
bone marrow-derived monocytes. Human and mouse studies have indicated that a 
large heterogeneity exists in MØ populations in lymphoid organs and non-lymphoid 
organs such as the lung (alveolar MØ), liver (Kupffer cells), spleen (white and red 
pulp MØ), peritoneum (peritoneal MØ) and nervous system (microglia) 46,47. These 
MØ subsets are phenotypically and functionally different, but all of them play broad 
roles in tissue remodeling and homeostasis 48. Depending on the cytokine 
environment, MØ can be activated classically (IFN-) or alternatively (IL-4 and IL-
13), as reviewed elsewhere 49,50. Similarly, in mice these subsets have been 
defined as type 1- (i.e., classically activated) or type 2- (i.e., alternatively activated) 
activated MØ 51, which are characterized as pro-inflammatory and anti-
inflammatory cells, respectively. However, it is not yet fully defined whether 
resident MØ are anti-inflammatory.
The growth and differentiation of MØ depends on lineage-determining cytokines 
such as granulocyte/macrophage colony-stimulating factors (GM-CSF) and M-CSF 
(also termed CSF-1) 50,52. Mice lacking M-CSF develop a general MØ deficiency 53, 
whereas GM-CSF-knockout mice have no major deficiency of MØ 54,55. Importantly, 
in humans, M-CSF, but not GM-CSF, is a ubiquitous cytokine circulating in the 
human body 56,57. Therefore, it is likely that M-CSF is the default cytokine to drive 
MØ differentiation under steady-state conditions.
Recently it has been shown that human MØ can be polarized in vitro into pro-
inflammatory (MØ1) and anti-inflammatory cells (MØ2) by GM-CSF and M-CSF, 
respectively 57-59. GM-CSF-driven MØ1 are characterized by high production of pro-
inflammatory cytokines such as IL-6, IL-12 and IL-23, whereas M-CSF-driven MØ2 
are characterized by high production of IL-10 in the absence of pro-inflammatory 
cytokines.  It should be noted that  M-CSF-driven MØ2 do not completely resemble
alternatively activated MØ or type 2-activated MØ with respect to their surface 
marker expression and cytokine production 50,60. For example, alternative activated 
MØ showed increased expression of mannose receptors (MR) 50, and type 2-
activated MØ secrete TNF- upon stimulation 60. However, in the case of M-CSF-
driven MØ2, low MR expression was found and these cells fail to secrete TNF-
59,61. Since MØ2 express the unique surface marker CD163 61, it is tempting to 
speculate that MØ2 reflect CD163+ highly phagocytic resident MØ in vivo 62. 
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Clearance of dying cells by MØ subsets 
The role of MØ in the uptake of apoptotic cells has been studied extensively. In 
mice, among various MØ subsets, bone marrow-derived MØ 63,64 and peritoneal 
MØ 65-68 have been widely used. Recently, also microglia 69 and liver macrophages 
70,71 have been investigated for their roles in the apoptotic cell removal, suggesting 
that tissue MØ are active in the removal of dying cells in various anatomical 
locations. Besides tissue MØ, murine MØ cell lines 72-74 are also able to actively 
phagocytose apoptotic cells. The data above clearly show that various MØ subsets 
actively recognize and ingest cells that underwent apoptosis. 
In human system, most studies were carried out in vitro by using peripheral blood 
monocyte-derived MØ, differentiated in the presence of GM-CSF 75, M-CSF 76, or in 
the absence of growth factors 77-80. These MØ can be activated by various factors. 
For example, activation of MØ by glucocorticoid augments phagocytosis of 
apoptotic cells 81,82.  Similarly, IL-10-activated MØ show an enhanced capacity for 
the uptake of apoptotic cells 83. These data indicate that the micro-environment 
influences the differentiation process of MØ and thereby modifies their functions as 
well. 
Recently, we compared the capacities for the uptake of apoptotic cells among three 
types of phagocytes iMoDCs, MØ1, and MØ2 generated from the same monocyte 
population, and found that MØ2 have the unique capacity to preferentially take up 
early apoptotic cells 59. We found that MØ2 have the capacity to take up early 
apoptotic cells more efficiently than late apoptotic or necrotic cells (four fold 
increase), and that this uptake was superior compared to that of MØ1 and iMoDCs. 
Thus we hypothesize that under steady-state conditions, scavenging of apoptotic 
cells is largely confined to a specialized subset of phagocytes with anti-
inflammatory properties. Other subsets of phagocytes might act as backups, or 
even be more involved in the resolution of inflammation and /or immune regulation. 
We propose that in the case of MØ, the anti-inflammatory MØ2 are the default 
phagocytes that take up early apoptotic cells in a silent manner, whereas excessive 
apoptotic cells progress to a late stage of cell death and might provide "eat me 
signals" to the non-resting phagocytes such as the pro-inflammatory MØ1. In the 
latter case, appropriate opsonization may determine the consequence of the 
uptake (Fig. 2). It is important to note that most opsonins, including C1q, MBL, 
PTX3 and SAP, preferentially bind to late apoptotic cells 13.
Consequence of uptake by MØ
A substantial number of in vitro studies have shown that MØ that have ingested 
apoptotic cells are inhibited in their production of pro-inflammatory cytokines 
63,65,74,79, consistent with the prevailing believe that apoptotic cells are removed by 
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MØ in a silent manner. Since both pro-inflammatory and anti-inflammatory MØ 
exist, a relevant question is then: do they respond to apoptotic cells in different 
ways? Our studies showed that upon ingestion of apoptotic cells, pro-inflammatory 
MØ1 down-regulate the production of pro-inflammatory cytokines, whereas anti-













Figure 2. Apoptotic cell uptake by MØ subsets. We propose that concerning MØ, at least two 
subtypes exist, i.e., the pro-inflammatory MØ1 and the anti-inflammatory MØ2. MØ2 preferentially 
bind and ingest early apoptotic cells in a non-inflammatory fashion. Excessive apoptotic cells 
progress to a late stage of cell death and might provide "eat me signals" to the non-resting 
phagocytes such as pro-inflammatory MØ1. In this case, appropriate opsonization of apoptotic 
cells may determine the consequence of the uptake.
Similar to DCs, not only apoptotic cells, but also necrotic cells are taken up by MØ 
84,85. Like for apoptotic cells, several studies have addressed the question whether 
necrotic cells activate MØ to trigger immunity. It has been shown that phagocytosis 
of necrotic cells by MØ does not induce inflammation 84,85. However, these findings 
were challenged in a recent publication showing that exposure of  MØ to early and 
late apoptotic cells induces identical signal transduction in these cells in terms of 
inhibition of ERK 1/2 and induction of JNK and P38, whereas necrotic cells induced 
an opposite signal transduction 86. Taken together, these data provide an 
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ambiguous image on whether necrotic cells are much more dangerous than 
apoptotic cells. Further studies will be required to understand the interaction of MØ 
with the intracellular contents released from necrotic cells such as HSP 87, HMGB1 
88 and uric acid 89. 
Like DCs, MØ are also professional APCs 47. It would be of interest to investigate 
how these intracellular molecules modulate MØ function including the presentation 
of autoantigens. Indeed, most available studies have not investigated the role of 
dying cell-derived antigen presentation on MØ. It has been suggested that MØ fail
to cross-present antigenic material contained within the engulfed apoptotic cells 33. 
In contrast to DCs that can retain antigen for at least 2 days 90, MØ robustly 
degrade the ingested antigens, and therefore may fail to promote T cell priming 91. 
Thus it remains to be investigated how MØ process antigens derived from dying 
cells and subsequently present these to Class I- or II-restricted T cells.
Concluding remarks
As discussed so far, there are different professional phagocyte subsets that are 
actively involved in the clearance of dying cells. Presumably, also neighboring non-
professional phagocytes might actively participate in the removal of dying cells. 
Therefore, especially under steady-state conditions, the fate of dying cells will 
ultimately be determined by local conditions and the composition of the tissue. 
Excessive apoptosis leads to the release of intracellular signals and therefore alert 
the immune system in various aspects. Again, the local environment will determine 
1) the composition of attracted phagocytes; 2) the presence of innate molecules 
that help in opsonization and clearance; or 3) presence of TLR ligands that might 
activate immunity. The sole presence of high amounts of apoptotic cells as a 
consequence in deficiencies in clearance, as shown in CD14-/- mice 92 or C1q-/-
mice 5 on a non-autoimmune background, does not always lead to a break of 
immunological tolerance. In vivo dissection of phagocyte subsets with distinct 
functional properties will be of particular importance to understand how the 
clearance of apoptotic cells by phagocytes is regulated and how this may lead to
induction or loss of peripheral tolerance.
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Summary
To prevent the development of autoimmunity, professional phagocytes including 
subsets of dendritic cells (DCs) and macrophages (MØ) promptly and efficiently 
clear apoptotic cells. Here we identify that M-CSF-driven macrophages (MØ2) are 
potent phagocytes that have the unique capacity to preferentially bind and ingest 
early apoptotic cells. This macrophage subset has intrinsic anti-inflammatory 
properties, characterized by high IL-10 production in the absence of pro-
inflammatory cytokines, such as IL-6 and TNF-. Importantly, whereas the IL-6 and 
TNF- production by GM-CSF-driven macrophages (MØ1) is inhibited upon uptake 
of apoptotic cells, the anti-inflammatory status of MØ2 is retained during 
phagocytosis. MØ2 were shown to use CD14 to tether apoptotic cells, whereas 
recognition of phosphatidylserine (PS) contributed to uptake of early apoptotic cells. 
MØ2 showed more potent macropinocytosis compared to DCs and MØ1, and 
uptake of apoptotic cells was inhibited by a macropinocytosis inhibitor.  Our studies 
suggest that, under steady-state conditions, IL-10-producing MØ2 are prominently 
involved in the clearance of early apoptotic cells.




During normal homeostasis and tissue turnover large numbers of cells undergoing 
apoptosis are promptly removed and replaced. The removal of apoptotic material 
plays an important role in the suppression of inflammation and the regulation of 
immune responses 1-3. Apoptotic cells are a rich source of autoantigens 4, which 
are involved in the physiologic maintenance of self-tolerance. The uptake and 
processing of apoptotic cells has been proposed to be a silent process, meaning 
that release of pro-inflammatory cytokines by phagocytes is prevented 5-8. Impaired 
clearance of apoptotic cells, resulting in an accumulation of late apoptotic and 
secondary necrotic cells, might provide a danger signal to antigen presenting cells 
(APCs), thus activating autoreactive T cells, and finally leading to the breakdown of 
peripheral tolerance 3. Accumulating evidence has been provided that defective
clearance of apoptotic cells can lead to exacerbation of inflammation and 
predisposes to the development of autoimmunity, such as in systemic lupus 
erythematosus (SLE) 9.
The apoptotic cell clearance machinery includes professional phagocytes, i.e. 
immature dendritic cells (DCs) and macrophages (MØ), and non-professional 
phagocytes, including epithelial cells, fibroblasts and mesangial cells 10. It has 
become clear that there are various subsets in both DCs and MØ 11-13. Recent in 
vitro data show that MØ can be polarized into pro-inflammatory (MØ1) and anti-
inflammatory cells (MØ2) by granulocyte/macrophage colony-stimulating factors 
(GM-CSF) and M-CSF (also termed CSF-1), respectively 14,15. Classically, GM-CSF 
and M-CSF are thought to be the primary growth factors for the differentiation of 
macrophages 16. Mice lacking M-CSF develop a general MØ deficiency 17, whereas 
GM-CSF-knockout mice showed no major deficiency of MØ 18,19. In humans, M-
CSF, but not GM-CSF, is an ubiquitous cytokine circulating in the human body 14,20. 
Thus, M-CSF could be the default cytokine to drive MØ differentiation under 
steady-state conditions. 
The removal of apoptotic cells is an ongoing and constitutive process. Apoptotic 
cells provide "eat me signals" to phagocytes to promptly and efficiently engulf 
apoptotic cells during the very early stage of cell death, preventing them to release 
noxious intracellular contents 21. Although the silent removal of early apoptotic cells 
is well appreciated, the immunological mechanisms involved are incompletely 
defined. There are several checkpoints conceivable which together determine the 
immunological response towards the clearance of apoptotic cells.  First, the 
process and the stage of cell death and/or the specific death pathways triggered 
are closely related to the consequence of apoptotic cell clearance 22. It has been 
established that late apoptotic or necrotic cells induce phagocyte activation 
whereas early apoptotic cells do not 23,24. This is most likely due to differential 
expression of markers of cell death, such as heat shock proteins 25, HMGB1 26 and 
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uric acid 27. Second, opsonization of apoptotic cells by components of the innate 
immune system such as complement factors facilitates and modulates the 
clearance of apoptotic cells (reviewed in 28). Third, the nature of phagocytes that 
take up apoptotic cells might provide a defined immunological response. 
Due to the large heterogeneity of phagocytes, the contribution of different 
phagocyte subsets in the clearance of apoptotic cells in terms of cytokine signature 
and the polarization of immune regulation remains largely unknown. In this respect, 
we hypothesize that under steady-state conditions, the scavenging of apoptotic 
cells is largely confined to a specialized phagocyte subset with anti-inflammatory 
properties. To test this hypothesis, we compared three types of phagocytes, DC, 
MØ1 and MØ2, with respect to the phagocytosis of apoptotic cells at various 
stages of cell death. Our results strongly suggest that IL-10-producing MØ2 are 
prominently involved in the recognition and clearance of early apoptotic cells.
Materials and Methods 
Generation of monocyte-derived DCs, MØ1 and MØ2.
Human mononuclear cells were isolated from buffy-coats obtained from healthy donors using Ficoll-
Hypaque (Sigma-Aldrich, St. Louis, MO), followed by anti-CD14 microbeads magnetic cell sorting, 
according to the manufacturer's instruction (Miltenybiotec/CLB, Amsterdam, the Netherlands). DCs were
generated in 6-well culture plates (Costar, Cambridge, MA) in RPMI culture medium (RPMI 1640 
containing 10% heat-inactivated FCS, 90 U/ml penicillin and 90 g/ml streptomycin) (all from Gibco/Life 
technologies, Breda, the Netherlands) supplemented with 5 ng/ml GM-CSF (Leucomax, Novartis 
Pharma BV, Arnhem, the Netherlands) and 10 ng/ml IL-4 (PeproTech, Rocky Hill, NJ) for at least 6 days, 
as previously described 29. Two types of macrophages, namely MØ1 and MØ2, were generated in the 
same RPMI culture medium as DCs but supplemented with 5 ng/ml GM-CSF and 5 ng/ml M-CSF (R&D 
systems / ITK Diagnostics, Uithoorn, the Netherlands), respectively. In some experiments, MØ2 were 
generated in the presence of M-CSF and 10 g/ml neutralizing anti-IL-10-receptor mAb 30. In all 
experiments comparing these three types of phagocytes, they were generated in parallel from 
monocytes of the same donor. Separate unrelated donors were used for each independent experiment.
Analysis of cell surface molecules by flow cytometry.
Cells were harvested and washed in buffer containing 1% BSA, 1% heat-inactivated normal human 
serum, and 0.02% NaN3. The following mAbs were used for flow cytometry analysis to analyze the 
surface molecules of phagocytes: anti-CD1a (Leu-6), anti-CD14 (Leu-M3), anti-CD11b/Mac-1 (all from 
BD Biosciences, San Jose, CA), anti-DC-SIGN/CD209 (AZN-D1, a gift of Dr. Y. van Kooyk, VU Medical 
Center, Amsterdam, the Netherlands), and anti-mannose receptor (MR) /CD206 (D547.3, a gift of F. 
Koning, LUMC, Leiden, the Netherlands). Staining was visualized by PE-conjugated goat anti-mouse Ig 
(Dako, Glostrup, Denmark) using appropriate isotype controls. Cells were analyzed using FACSCalibur 
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and CellQuest software (BD Biosciences). Dead cells, identified by propidium iodide (PI) uptake, were 
excluded from analysis.
Induction of apoptosis and necrosis.
Jurkat T cells were cultured in RPMI culture medium. Apoptosis of Jurkat T cells was induced by culture 
with 50 M etoposide (Vepesid, Bristol-Myers Squibb, New York, NY, USA) for 18 h in serum-free RPMI 
culture medium (RPMI 1640 containing 90 U/ml penicillin and 90 g/ml streptomycin). Alternatively, 
Jurkat cells were washed with PBS and exposed to ultra violet (UV)-C light (TUV lamp, predominantly 
254 nm, Philips electronic Instruments Inc., Eindhoven, the Netherlands) at a dose of 50 J/m2. After UV 
irradiation, cells were cultured for 4 and 30 hours in serum-free RPMI medium to harvest the early and 
late apoptotic cells, respectively. Necrosis was induced by incubating Jurkat cells at 56C in a water 
bath for 1 hour. Both apoptosis and necrosis were confirmed by double staining with fluorescein 
isothiocyanate (FITC)-labeled annexin V and propidium iodide (PI, VPS Diagnostics, Hoeven, the 
Netherlands) according to established methods 31.
Next to apoptotic and necrotic cells, apoptotic blebs were used. Blebs were isolated from Jurkat cells 
treated with 50 M etoposide for 48 h, as described before 32. Blebs from 2.5×105 cells were used for 
the phagocytosis assay (see below) per 1×105 phagocytes. 
Phagocytosis assay.
Prior to the induction of apoptosis, Jurkat cells were fluorescently labeled with carboxyfluorescein 
diacetate succinamidyl ester (CFSE, Molecular Probes, Leiden, the Netherlands), according to a 
previously described method 33. In brief, Jurkat cells were suspended in PBS at 2×107 cells/ml and 
incubated for 30 min at 37C with 5 M CFSE. Cells were washed and resuspended at 2×106 cells/ml in 
serum-free RPMI culture medium, used for apoptosis induction, as described above. For the 
phagocytosis assay, labeled apoptotic cells (1×105) were co-cultured with DCs, MØ1 or MØ2 at 1:1 ratio 
for different time periods at 37C or 4C in 250 l RPMI culture medium in round-bottom glass tubes. 
DCs, MØ1 or MØ2 were stained with a PE-conjugated mAb against CD11b or APC-conjugated mAb 
against CD14 (BD Biosciences) and uptake was analyzed by two-color flow cytometry. The percentage 
of CD11b-positive cells that stained positive for CFSE was used as a measure for the percentage of 
DCs, MØ1 and MØ2 that ingested (37C) and/or bound (4C) apoptotic cells. 
Phagocytosis of apoptotic cells by MØ1 and MØ2 was further investigated by confocal laser scanning 
microscopy with a BioRad MRC1024 ES krypton–argon ion laser scanning imaging system (Hercules, 
CA), using appropriate filter settings. Images were visualized using a 40x/0.75 numeric aperture (NA) oil 
objective, were acquired using Laser Sharp 2000 software (BIO-Rad), and were processed using 
ImageJ software version 1.33 (NIH Image, Bethesda, MD). For this purpose, CFSE-labeled apoptotic 
cells (1×105) and phagocytes were co-cultured at 1:1 ratio on the Lab-TEKTM chamber slides 
(NUNC/Sanbio, Uden, the Netherlands) for 2 h at 37C, followed by washing to remove the non-
ingested apoptotic cells, and staining with PE-conjugated mAb against CD11b. Cells were fixed with 4% 
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paraformaldehyde before analysis. More than 600 single cells of MØ1 or MØ2 were randomly scored. 
Phagocytosis was presented as phagocytic index (percentage of phagocytosing MØ × average number 
of apoptotic cells per MØ) 34.
To measure a general phagocytic capacity of MØ1 and MØ2, sheep red blood cells (SRBC, 
erythrocytes) were obtained and opsonized with rabbit anti-sheep red blood cell IgG (EIgG). MØ1 and 
MØ2 were pre-cultured on Lab-TEKTM chamber slides at 37C, followed by the addition of EIgG or non-
opsonized erythrocytes at 1:50 ratio for 0.5 h. Unbound erythrocytes were washed away with PBS and 
uningested erythrocytes were lysed by lysis buffer. Cells were fixed and stained with May-Grünwald 
/Giemsa. More than 300 single cells of MØ1 or MØ2 were scored by the light microscopy and 
phagocytosis was presented as phagocytic index. 
Cytokine detection.
DCs, MØ1 and MØ2 were stimulated with 200 ng/ml lipopolysaccharide (LPS, Salmonella Typhosa, 
Sigma-Aldrich) for 24 h and supernatants were harvested. Cytokines were detected in the supernatants 
using ELISA. The measurements of IL-6 and TNF- were performed as described  35. The analysis of IL-10 
was performed according to the manufacturer's instructions (Sanquin Research, Amsterdam, the 
Netherlands). 
Co-culture was performed by incubating DCs, MØ1 and MØ2 with etoposide-induced apoptotic cells at a 
1:1 ratio in RPMI culture medium. After 24 h, supernatants were harvested and tested for IL-6, IL-10 and 
TNF- production.
Endocytosis and macropinocytosis assays.
Lectin-mediated endocytosis was examined following co-incubation of phagocytes (1×105) with 100 
µg/ml DextranFITC (Molecular Probes) for 30 or 60 min at 37C in RPMI culture medium. Control 
experiments were done at 4C. Blocking experiments were performed by pre-incubation of phagocytes 
for 20 min with 100 µg/ml mannan, or 50 mM D-mannose (both from Sigma-Aldrich). Incubation with 50 
mM L-mannose (Sigma-Aldrich) or culture medium only was used as a negative control. 
Macropinocytosis was measured as the cellular uptake of 100 µg/ml lucifer yellow (LY) dipotassium salt 
(Molecular Probes) or 0.2 µg/ml BSAFITC (Sigma-Aldrich). Cells were washed extensively with cold PBS 
containing 1% FCS and 0.02% NaN3. Before analysis with flow cytometry, the cell surface fluorescence 
was quenched with trypan blue (Sigma-Aldrich). To quantify the uptake, mean fluorescence intensity
(MFI) values obtained at 4C were subtracted from MFI values obtained at 37C. 
Inhibition of uptake of apoptotic cells
To assess the role of phosphatidylserine (PS) in the uptake of early apoptotic cells by MØ2, early 
apoptotic cells were pre-incubated with recombinant annexin V (Sigma-Aldrich) (up to 50 µg/ml) at 4ºC 
for 20 min to mask PS, before incubation with MØ2. To assess the role of CD14 in the apoptotic cell 
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clearance, MØ1 and MØ2 were treated with an anti-CD14 blocking mAb (61D3, a kind gift of Dr. C. 
Gregory, University of Edinburgh, U.K.). MØ were pre-incubated with 61D3 (20 µg/ml) for 20 min at 4ºC
before addition of UV-induced early apoptotic cells or etoposide-induced apoptotic cells.
To investigate the role of macropinocytosis in the uptake of apoptotic cells by MØ1 and MØ2, 5-(N, N-
Dimethyl)amiloride hydrochloride (DMA, Sigma-Aldrich) was used to inhibit macropinocytosis. MØ1 and 
MØ2 were pre-incubated with DMA (up to 1 mM) at 37ºC for 20 min before early apoptotic cells or 
apoptotic blebs were added.
Statistical analysis.
Statistical analysis was performed by two-way ANOVA, Chi-square or one sample t test using 
GraphPad Prism (GraphPad software, San Diego, CA). Differences were considered statistically 
significant when p values were less than 0.05.
Results
Characterization of DCs, MØ1 and MØ2.
Three types of phagocytes were generated from peripheral blood monocytes by 
different cytokines, i.e. IL-4 and GM-CSF for DCs, GM-CSF for MØ1, and M-CSF 
for MØ2, respectively. MØ2 were less-adherent cells, with irregular shapes 
compared with MØ1 (Fig. 1A). In contrast to DCs, MØ1 and MØ2 shared the typical 
macrophage phenotype, being positive for CD14, but negative for CD1a and DC-
SIGN (Fig. 1B). Notably, MØ2 expressed higher levels of CD14, but much lower 
level of mannose receptors (MR) than MØ1. All three cell types showed expression 
of CD11b. 
Uptake of apoptotic cells by DCs, MØ1 and MØ2.
To investigate the phagocytosis of these three phagocyte subsets, apoptosis was 
induced in Jurkat cells using etoposide for 18 hours at 37C in serum-free RPMI 
culture medium, as described before 32. According to annexin V and PI staining, 
early apoptotic cells (Annexin+PI- populations) were routinely 27.52  6.08 % and 
late apoptotic cells (PI+ populations) were 48.61  10.76 % (n=8). Apoptosis was 
confirmed by nuclear fragmentation using Hoechst staining (data not shown). 
Exposure of apoptotic cells to DCs, MØ1 and MØ2 resulted in a time- and 
temperature-dependent binding and ingestion, as shown by the appearance of 
CFSE- and CD11b-double positive populations (Fig. 2A). Notably, from the three 
types of cells, MØ2 demonstrated the highest capacity for binding of apoptotic cells 
at 4C, and for uptake of apoptotic cells at 37C (Fig. 2A). MØ2 have a 1.5 to 2-fold 
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higher capacity for both binding and uptake of apoptotic cells compared to DCs and 
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ratios of phagocytes:apoptotic cells (4:1, 16:1, and 64:1) were applied during co-
culture (data not shown). The uptake was significantly increased in time at 37C 
(ANOVA, p<0.05 for all three type of phagocytes), but the binding at 4C was 
stable (Fig. 2B). 
To confirm and quantify the uptake of apoptotic cells by MØ1 and MØ2, confocal 
microscopy was used. This analysis clearly showed the presence of CFSE-labeled 
apoptotic material inside the cells (Fig. 2C). Quantification of phagocytic index 
confirmed our FACS data that MØ2 were more potent in the uptake of apoptotic 
cells than MØ1 (Fig. 2D). The higher phagocytic index in MØ2 was due to a 
significantly higher percentage of MØ2 contributing to the uptake as compared to 
MØ1 (Chi-square test, p<0.0001), whereas the number of apoptotic cells taken up 
per macrophage between MØ1 and MØ2 were similar (2.33 vs 2.55, respectively). 
We realize that the difference of uptake between the quantification measured by 
FACS and by confocal microscopy is large, which is probably due to several factors. 
First of all, data presented are from separate sets of experiments with cells derived 
Figure 1. Characterization of 
DCs, MØ1 and MØ2. (A) DCs, 
MØ1 and MØ2 were generated 
in parallel from the same donor 
cultured for 6 or 7 days. 
Pictures show the morphology 
of these 3 different types of 
cells. Images were obtained 
using an Axiovert 25 inverted 
microscope (Carl Zeiss, 
Sliedrecht, the Netherlands) 
with a 20 x/0.3 NA objective 
and Zeiss Axiovision software 
version 3.1. Magnification 
200×. (B) Surface expression 
of CD1a, CD14, DC-SIGN, 
mannose receptor (MR) and 
CD11b on DCs, MØ1 and MØ2 
was determined by flow 
cytometry after 6 days of 
culture (closed histograms). 
Open histograms represent 
matched isotype controls. Data 
are representative of 3 to 8 
independent experiments. 
Separate unrelated donors are 




from different donors. We have not performed a side-by-side comparison of both 
techniques. Second, for FACS analysis, we were using the cells in solution, which 
might affect their phagocytic behavior. However, in all cases MØ1 and MØ2 were 
generated in parallel from the same donor. Therefore we think we can draw firm 
conclusions from the comparisons between MØ1 and MØ2.
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Figure 2. Uptake of apoptotic 
cells by DCs, MØ1 and MØ2. (A) 
Jurkat T cells were labeled with 
CFSE and induced into apoptosis 
by treating cells with etoposide for 
18 hours. Apoptotic cells (0.1106
cells) were co-incubated with DCs, 
MØ1 or MØ2 at 1:1 ratio, for 0.5 h 
and 2 h at 37C or 4C. Prior to 
flow cytometry analysis, cells were 
stained with PE-conjugated mAb 
against CD11b. CFSE- and 
CD11b-double positive 
populations represent the 
phagocytes that have bound 
and/or ingested apoptotic cells. 
Dot-plots represent the 
phagocytosis of apoptotic cells at 
2 h. (B) The percentage of uptake 
and binding (at 37C) or binding 
(at 4C) were calculated as 100% 
 ((CD11b+CFSE+)/CD11b+). Data 
indicate the mean  SD from 4 
independent experiments 
performed in duplicate. Statistics 
were performed with two-way 
ANOVA. *, p<0.01, **, p<0.001. 
(C) Confocal microscopy images 
show the uptake of apoptotic cells 
by MØ1 and MØ2 (see arrows). 
Red cells represent the CD11b-PE 
positive MØ and green ones are 
the CFSE-labeled apoptotic cells. 
(D) Based on the confocal images, 
more than 600 cells of MØ1 and 
MØ2 were scored. Data are 
presented as phagocytic index 
(percentage of phagocytosing MØ 
× average number of apoptotic 
cells per MØ). A Chi-square test 
was performed to evaluate the 
difference in the capacity of 
apoptotic cell uptake between 
MØ1 and MØ2 (p<0.0001). (E) 
Sheep erythrocytes were 
opsonized with rabbit anti-sheep 
red blood cell IgG (EIgG) and co-
cultured with MØ1 and MØ2 on 
Lab-TEKTM chamber slides at 
37C for 0.5 h, followed by May-
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To determine whether the observed highly phagocytic capacity of MØ2 represent a 
generalized increase on phagocytosis, uptake of EIgG was investigated. We found 
that the phagocytic index of MØ2 is 6.84 fold higher than that of MØ1 (mean of 3 
independent experiments) (Fig. 2E, F). This is especially explained by the fact the 
percentage of MØ2 contributing to the uptake was significantly higher than that of 
MØ1 (Chi-square test, p<0.0001 for all three independent experiments), whereas 
the number of erythrocytes taken up per macrophage between MØ1 (1.83  0.17) 
and MØ2 (2.23  0.72) showed no difference (paired t test, p=0.40). The non-
opsonized erythrocytes were not ingested by MØ1, whereas the uptake by MØ2 
was of low efficiency (phagocytic index <0.1, data not shown). Together, these 
data clearly show that MØ2 have a more generalized higher capacity of 
phagocytosis than MØ1.
MØ2 retain their anti-inflammatory status after uptake of apoptotic cells. 
It has been proposed that clearance of apoptotic material is a non-inflammatory 
process 1-3. Therefore we investigated the functional consequences of uptake of 
apoptotic cells by MØ1 or MØ2 by measuring the cytokine release in supernatants. 
The capacity of cytokine production by the three phagocyte subsets was first 
investigated using LPS stimulation (Fig. 3A-C). LPS-stimulated MØ2 produced 
large amounts of IL-10, but failed to secrete IL-6 and TNF-. In contrast, MØ1
produced high amounts of IL-6 and TNF- after LPS stimulation, whereas IL-10 
was hardly detectable. DCs derived from the same donor were able to produce IL-
10, IL-6 and TNF- following LPS stimulation. 
MØ2 showed intrinsic IL-10 production (Fig. 3A, D), which was retained after 
uptake of apoptotic cells (Fig. 3D), whereas production of IL-6 or TNF- was not 
induced (Fig. 3E-F). Importantly, uptake of apoptotic cells by MØ1 resulted in a 
down-regulation of IL-6 and TNF- production, but no induction of IL-10 (Fig. 3D-F). 
Upon exposure to apoptotic cells, DCs did not secrete IL-10, IL-6 or TNF-. 
MØ2 preferentially take up early apoptotic cells.
To assess whether there are differences among these three types of phagocytes in 
the uptake of apoptotic cells in different stages of cell death, Jurkat cells were 
exposed to UV light. Four hours after UV irradiation, around 50-70% early apoptotic 
cells (annexin V+ / PI-) were obtained (Fig. 4A). Thirty hours after UV irradiation, 
around 70-95% of cells were late apoptotic (PI+). Necrotic cells generated by heat 
shock were all PI-positive. Viable cells were used as a negative control. All three 
types of phagocytes were unable to take up viable cells (Fig. 4B). Importantly, MØ2
were the only phagocytes that were able to distinguish early apoptotic cells from 
late apoptotic and necrotic cells.  MØ2 have a preferential uptake of early apoptotic 
cells, compared to late apoptotic or necrotic cells (Fig. 4B). In contrast, DCs and 
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MØ1 show an equal efficiency in the uptake of early apoptotic, late apoptotic or 
necrotic cells. Furthermore, the efficiency of taking up early apoptotic cells by MØ2 
is at least 2-fold higher than that by DCs and MØ1 (mean  SD of phagocytosis of 



































































































Figure 3. Cytokine production by DCs, MØ1 and MØ2 after LPS stimulation or uptake of 
apoptotic cells. (A-C) Day-6 DCs, MØ1 and MØ2 were extensively washed, and subsequently 
stimulated with or without LPS for 24h. (D-F) DCs, MØ1 or MØ2 (1105 cells) were co-cultured with 
etoposide-induced apoptotic cells at a 1:1 ratio for 24 h in RPMI culture medium. Supernatants were 
harvested and measured by ELISA for IL-10, IL-6, and TNF-.  Data are presented as mean ± SD 
from duplicate cultures and are representative of at least 3 independent experiments where cells are 
generated from separate unrelated donors. Dashed lines represent the detection limits of ELISA.
It has been show that IL-10-activated MØ have increased phagocytic capacity for 
the uptake of apoptotic cells 36. To investigate whether IL-10-producing MØ2 
become highly phagocytic to early apoptotic cells as a consequence of the IL-10 
environment created by themselves, we generated MØ2 in the presence of 
neutralizing anti-IL-10-receptor mAb. Although the anti-IL-10-receptor mAb 
inhibited the endogenous IL-10 production of MØ2 (data not shown), it did not 
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inhibit phagocytosis of early apoptotic cells as compared to MØ2 generated in the 
absence of anti-IL-10-receptor mAb (Fig. 4C). We conclude that endogenous IL-10 
produced by MØ2 is not involved in driving the development of high capacity for 









































































































Figure 4. Uptake of viable, early apoptotic, late apoptotic, and necrotic cells by DCs, MØ1 
and MØ2. (A) Early and late apoptotic cells were induced by UV-C light at a dose of 50 J/m2, then 
cultured for another 4 and 30 h, respectively. Necrosis was induced by incubating Jurkat cells at 
56C for 1 hour. The untreated viable cells were used a control. Apoptosis was confirmed by 
double staining with FITC-labeled annexin V and propidium iodide (PI). (B) These CFSE-labeled 
cells were co-cultured with DCs, MØ1 or MØ2 (1105 cells) at 1:1 ratio, in the same way as 
described at Fig. 2. The percentages of uptake and binding (at 37C) or binding (at 4C) were 
quantified similarly as described at Fig. 2.  Data represent at least 3 independent experiments 
performed in duplicate. (C) Uptake of early apoptotic cells by MØ2 generated in the presence or 
absence of 10 g/ml neutralizing anti-IL-10-receptor mAb. 
Role of PS and CD14 in the uptake of apoptotic cells by MØ1 and MØ2.
A major feature of early apoptosis is the redistribution of PS from the inner layer of 
the cell membrane to the outside. Therefore we next investigated whether PS is 
involved in the phagocytosis by MØ2. Pre-incubation of early apoptotic cells with 
non-labeled annexin V prevented binding of FITC-labeled annexin V, confirming an 
effective masking of PS (data not shown), as described before 32,37. The uptake of
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early apoptotic cells by MØ2 was partially inhibited after PS masking (inhibition was 
between 6.5% to 23.2% in three independent experiments), and this effect could 
not be improved by applying a higher concentration of annexin V (Fig. 5A). 
CD14 has been shown to be involved in the recognition of apoptotic cells by MØ 38.
As a possible explanation for their efficient uptake of apoptotic cells, we noticed 
that MØ2 express a significantly higher level of CD14 compared to MØ1 (Fig. 1B 
and Fig. 5B). Surface expression of CD14 on MØ1 is heterogeneous (Fig. 1B). 
Based on the FACS dot-plots, MØ1 were equally divided into two populations: 
CD14high and CD14low (Fig. 5C). Phagocytosis experiments showed that CD14high
cells were twice as efficient in binding and uptake of apoptotic cells compared to 
CD14low cells (Fig. 5C). Thus we further investigated the role of CD14 in the 
engulfment of early apoptotic cells by using a blocking antibody against CD14, 
mAb 61D3 38. The uptake of early apoptotic cells by both MØ1 and MØ2 was not 
significantly inhibited by this mAb. We did observe that the binding of early 
apoptotic cells by MØ2 at 4ºC was inhibited (p<0.001) (Fig. 5D). Similar data were 
obtained when apoptosis was induced with either UV or etoposide. Together, these 
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Figure 5. Role of PS and CD14 in the uptake of early apoptotic cells by MØ1 and MØ2. (A) 
CFSE-labeled early apoptotic cells were pre-incubated with 10 g/ml or 50 g/ml unlabeled 
annexin V or medium as control at 4C for 20 min, before the co-incubation with MØ2.  The 
percentage of uptake and/or binding was calculated as described in Figure 2. Data shown are 
representative of 3 independent experiments performed in duplicate. (B) CD14 expression on DCs, 
MØ1, and MØ2 generated in parallel from the same donor. Bars show the mean fluorescence 
intensity (MFI). Data shown are the mean ± SD from 4 independent experiments. (C) After co-
incubation of apoptotic cells with MØ1, cells were stained with a APC-conjugated anti-CD14 mAb, 
instead of anti-CD11b. CD14 expression was divided equally into two populations: CD14high and 
CD14low. Dot-plots of the FACS showed the distinct uptake of apoptotic cells by CD14high and 
CD14low cells. (D) MØ1 and MØ2 were pre-incubated with or without a blocking anti-CD14 antibody 
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(mAb 61D3) at 4C for 20 min., before the co-incubation with early apoptotic cells for 2 h. Relative 
uptake / binding was calculated as 100%  (% in the presence of anti-CD14) / (% in the absence of 
anti-CD14). Data are shown as mean ± SD from 4 (MØ1) to 6 (MØ2) independent experiments 
performed in duplicate. Similar results were obtained when etoposide-induced apoptotic cells were 
applied. **, p<0.001, one sample t test. Separate unrelated donors are used for each independent 
experiment. Dashed line indicates 100% of relative uptake.
Uptake of early apoptotic cells by MØ2 is mediated by macropinocytosis.
Phagocytes take up antigens via receptor-mediated endocytosis mostly by C-type 
lectins, such as mannose receptors (MR), or via macropinocytosis (fluid phase 
endocytosis) 39,40. Therefore, we investigated lectin-mediated endocytosis of 
soluble antigens using DextranFITC. Despite the fact that MØ2 showed a 
significantly lower expression of MR (Fig. 1B and Fig. 6A), the uptake of 
DextranFITC by MØ1 and MØ2 was comparable, whereas uptake by DCs was more 
efficient (Fig. 6B). The uptake of DextranFITC by DCs and MØ1 was completely 
inhibited by mannan or D-mannose, whereas L-mannose, used as a negative 
control, did not inhibit the uptake (Fig. 6C). In contrast, pre-treatment of MØ2 by 
mannan or D-mannose inhibited the uptake of DextranFITC only by 50% (Fig. 6C), 
suggesting the involvement of lectin-independent mechanisms such as 
macropinocytosis. Indeed, for the uptake of both BSAFITC and LY, MØ2 were shown 
to be 2- to 3-fold more efficient compared to MØ1 and DCs (ANOVA, p<0.001) (Fig. 
6D, 6E). 
To investigate a possible contribution of macropinocytosis in the uptake of early 
apoptotic cells by MØ2, DMA, a Na+/H+ antiporter blocker, was used to inhibit the 
fluid phase uptake by macropinocytosis 39. DMA treatment of MØ2 not only 
inhibited the uptake of both BSAFITC and LY (Fig. 7A), but also inhibited the uptake 
of early apoptotic cells in a dose-dependent fashion (Fig. 7B), without interfering 
with the viability of the cells. Similarly, DMA also inhibited the uptake of early 
apoptotic cells by CD14high MØ1 (Fig. 7C). 
We next investigated the uptake of microparticles derived from apoptotic cells 
(apoptotic blebs). MØ2 were able to take up apoptotic blebs twice as efficiently as 
MØ1 (Fig. 7D). DMA inhibited the uptake of apoptotic blebs by MØ2 dose-
dependently (Fig. 7E), and in concentrations that are lower than needed for the 
inhibition of uptake of early apoptotic cells.
Discussion
Over the last few years, it has become clear that both DCs and MØ show a large 
heterogeneity 11,13. We hypothesized that distinct phagocyte subsets contribute 
differentially to the clearance of apoptotic cells. Here we identify that the IL-10-
producing MØ2 are potent phagocytes that have the unique capacity to 
preferentially bind and ingest early apoptotic cells. This macrophage subset has 
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intrinsic anti-inflammatory properties, characterized by high IL-10 production in the 
absence of pro-inflammatory cytokines, such as IL-6 and TNF-. IL-10 is an 
important anti-inflammatory cytokine, which is able to limit and ultimately terminate 


























































































Figure 6. Lectin-mediated endocytosis and macropinocytosis by DCs, MØ1 and MØ2. (A) 
Mannose receptor (MR)/CD206 expression on DCs, MØ1, and MØ2. Bars show the mean 
fluorescence intensity (MFI). Data shown are the mean (± SD) from 2 to 3 independent 
experiments. (B) The uptake of DextranFITC (100 µg/ml) by DCs, MØ1, and MØ2 was measured at 
1 h. Data shown are the mean ± SD from 3 independent experiments. (C) The uptake of 
DextranFITC was measured by different phagocytes pre-incubated with 100 µg/ml mannan, or 50 
mM D-mannose or L-mannose. The uptake by untreated phagocytes (control) is considered as 
100%, and data show the relative uptake against the control. Data represent 3 independent 
experiments. (D) The uptake of BSAFITC (0.2 µg/ml) by DC, MØ1, and MØ2 at 1 h.  Data shown are 
the mean ± SD from 5 independent experiments. (E) The uptake of lucifer yellow (LY) (100 µg/ml) 
by DCs, MØ1, and MØ2 at 1 h. Data shown are the mean ± SD from 3 independent experiments 
(**, p<0.001, ANOVA).  
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Figure 7. Uptake 
of early apoptotic 
cells and 
apoptotic blebs 
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MØ2. (B) Data 
show the dose-
dependent effect of 
DMA on uptake 
(37C-4C) of 
apoptotic cells and 
LY by MØ2 and 
represent the 
relative uptake of 
DMA-treated MØ2 
against the controls (untreated cells).  Data represent 4 independent experiments. (C) MØ1 were 
treated with or without 500 µM DMA at 37C for 20 min before the co-incubation with early 
apoptotic cells for 30 min. Data show the quantification of uptake (37C-4C) by CD14high and 
CD14low cells. Data represent 3 independent experiments. (D) Apoptotic blebs were isolated from 
CFSE-labeled Jurkat cells and were used for the phagocytosis assay with MØ1 and MØ2. Data 
represent 4 independent experiments. (E) MØ2 were pre-treated with or without DMA (up to 500 
M). Relative uptake is shown. Similar results were obtained from 2 independent experiments. 
Separate unrelated donors are used for each independent experiment.
The generation of apoptotic cells is a continuous process. Although it is generally 
accepted that clearance of apoptotic cells is a non-inflammatory process, this most 
likely happens only when apoptotic cells are removed during early stages of 
apoptosis progression. Late apoptotic or necrotic cells activate APCs, promoting 
them to present self-antigen to T cells, potentially resulting in autoimmunity 23,24. 
Thus under normal conditions, apoptotic cells should be cleared before they 
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progress into late stages. Our findings that MØ2 have the capacity to preferentially 
take up early apoptotic cells indicate that these IL-10-producing MØ subsets might 
be unique safeguards to promptly clear apoptotic cells in a silent way. To note, 
increased capacity of phgocytosis of apoptotic cells by MØ2 is not unique to 
apoptotic cells, but also to IgG-opsonized erytherocytes, suggesting MØ2 have a 
more generalized higher capacity of phagocytosis than MØ1. It remains to be 
established what the in vivo contribution is to apoptotic cell clearance by different 
myeloid subsets and which mechanisms underlie the specific clearance of early 
apoptotic cells. 
It has been shown that IL-10-activated MØ obtain enhanced capacity for the uptake 
of apoptotic cells 36. However, phagocytosis experiments using MØ2 generated in 
the presence of neutralizing anti-IL-10-receptor mAb suggested that endogenous 
IL-10 produced by MØ2 is not involved in driving the development of high capacity 
for phagocytosis of early apoptotic cells. This inconsistence could be due to the 
fact that Ogden et al. 36 generated MØ in the presence of IL-10 during 
differentiation process, whereas MØ produced low level of IL-10 during MCS-driven 
differentiation. It is surprising that neutralizing anti-IL-10-receptor mAb inhibited the 
IL-10 production during differentiation of MØ2. It remains unclear whether 
endogenour IL-10 is required to signal to IL-10R on MØ2, thus stimulating MØ2 to 
produce IL-10. 
Both GM-CSF and M-CSF are key growth factors, not only for MØ generation in 
vitro, but also for MØ differentiation in vivo. Op/op mice lacking M-CSF develop a 
profound macrophage deficiency, and this could be partially corrected by the 
implantation of diffusion chambers containing M-CSF-producing cells 17, confirming 
that M-CSF is crucial in MØ differentiation. GM-CSF knockout mice did not show 
major deficiency of MØ, although the MØ are smaller than normal 18,19. Under 
steady-state conditions, M-CSF is the only primary MØ growth factor detectable in 
peripheral blood 20. In contrast, GM-CSF is generally viewed as a pro-inflammatory
cytokine involved in inflammation and is hardly detectable in circulation 42. Thus 
under steady-state conditions, M-CSF could be the default cytokine driving MØ 
differentiation. 
Cell-cell contact with apoptotic cells is sufficient to induce profound inhibition of IL-
12 production by activated macrophages, thus preventing them to mount an 
immune response 8. We show here that, upon uptake of apoptotic cells, MØ2 do 
not produce pro-inflammatory cytokines such as IL-6 and TNF-, while their IL-10 
production was not inhibited. Importantly, and in line with previous results, uptake 
of apoptotic cells by MØ1 resulted in a down-regulation of IL-6 and TNF-
production. It has been shown that monocyte-derived MØ differentiated with M-
CSF acquire the ability to selectively induce T cell apoptosis in an activation-
specific fashion 43, leading to the speculation that peripheral tolerance can be 
helped by selectively deleting autoreactive T cells that respond to self-antigen. 
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Therefore, at least two mechanisms might be operational to prevent that uptake of 
apoptotic cells leads to immune activation.
Recently, CD14 has been reported to play an important role in the recognition of 
apoptotic cells 38 and was further suggested as a tethering molecule for MØ to 
recognize apoptotic cells 44. CD14-/- mice showed a persistence of apoptotic cells, 
supporting that CD14 plays a broad tethering role in the apoptotic cell clearance in 
vivo 45. In our study, CD14 expression is remarkably different between MØ1 
(CD14+) and MØ2 (CD14+++). Notably, MØ2 have a strong interaction with 
apoptotic cells already at 4C. Blocking studies using anti-CD14 antibody showed 
that CD14 is mainly involved in the surface binding, but hardly in the uptake of 
apoptotic cells, supporting the notion that CD14 is a tethering molecule rather than 
an engulfing molecule 38. 
Next to the tethering process, other mechanisms are involved in the engulfment of 
apoptotic cells. Uptake of antigens (Ag) takes place via at least two different 
pathways: receptor-mediated endocytosis and macropinocytosis 39,40. Although 
macropinocytosis is thought to be a specific characteristic of DCs 39, it can be 
induced in other cells, including  MØ stimulated with M-CSF 46,47. Here we show in 
a side-by-side comparison that MØ2, generated in the presence of M-CSF but 
tested in the absence of M-CSF, exhibit more potent macropinocytosis compared 
with monocytes-derived DCs. The suggestion that macropinocytosis contributes to 
the uptake of apoptotic cells has already been put forward 48. Engagement of MØ
surface receptors by apoptotic cells, either directly (via PS) or indirectly (via C1q or 
mannose binding lectin (MBL) binding to apoptotic cells) actively promotes 
macropinocytosis 34,49. Our studies using the inhibitor DMA suggest that the 
efficient uptake of early apoptotic cells or apoptotic blebs by MØ2 is mediated by 
Na+/H- antiporter-dependent macropinocytosis. Rac, Rho and Cdc42 have been 
described as the major regulators of actin-driven macropinocytosis 50. Whether 
these regulators are involved in initiating macropinocytosis, particularly in the 
uptake of early apoptotic cells by MØ2, remains to be established. Our findings are 
in agreement with the proposal that the uptake of apoptotic cells is a two-step 
process 3: first, apoptotic cells are engaged with phagocytes by receptor-
dependent tethering processes such as CD14 for MØ2; Second, formation of fluid-
filled macropinosomes allows MØ2 to promptly and efficiently engulf early apoptotic 
cells or microparticles-derived from apoptotic cells.  
In conclusion, different subsets of phagocytes, such as DCs, MØ1 and MØ2 
recognize and process early and late apoptotic cells in a differential manner. The 
cytokine environment and the nature of phagocytes at a certain location contribute 
to the decision whether apoptotic cells are cleared in a silent or inflammatory 
fashion. In this respect, we demonstrate that IL-10-producing MØ2 have the unique 
capability to preferentially bind and ingest early apoptotic cells. Our studies suggest 
that under steady-state conditions, M-CSF-driven MØ2 might be the default 
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phagocytes to preferentially clear early apoptotic cells in a silent way, thereby 
contributing to the induction and maintenance of peripheral tolerance after 
encountering self-antigen.
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Summary
We have recently shown that in vitro-polarized M-CSF-driven anti-inflammatory 
macrophages (Mφ2) have the unique capacity to preferentially bind and ingest 
early apoptotic cells. However, these data are based on in vitro polarized cells and 
it is unclear whether Mφ2-like cells exist in vivo. Here we used CD163 as a cell 
surface marker to distinguish Mφ2 from the pro-inflammatory Mφ1. We show that 
human peritoneal Mφ (pMφ) freshly isolated from patients on peritoneal dialysis 
have the phenotypical characteristics of Mφ2, including CD163 surface expression 
and lack of CD16. Like Mφ2, pMφ have the capacity for endocytosis and 
macropinocytosis, are able to preferentially bind and ingest early apoptotic cells, 
and produce large amounts of IL-10 upon stimulation with LPS. Moreover, upon 
LPS stimulation both pMφ and Mφ2 down-regulate CD86, resulting in a reduced 
capacity to stimulate proliferation of allogeneic T cells and an inhibition of Th1 
cytokine release of these T cells. Our data provide the evidence for the first time 
that in vitro-polarized Mφ2 exist in vivo, and human pMφ resemble the anti-
inflammatory Mφ2. We propose that pMφ have the potential to maintain an anti-
inflammatory condition in the peritoneal cavity.




The removal of apoptotic cells by phagocytes plays an important role in the 
suppression of inflammation and the regulation of immune responses 1,2. Since 
professional phagocytes including dendritic cells (DCs) and macrophages (Mφ) 
represent a very heterogeneous population of cells 3,4, the extent of clearance of 
apoptotic cells and its immunological consequence may depend on the nature of 
phagocyte subsets in a certain tissue compartment 5. We and others have recently 
shown that human Mφ can be polarized in vitro into pro-inflammatory (Mφ1) and 
anti-inflammatory cells (Mφ2) by granulocyte/macrophage colony-stimulating 
factors (GM-CSF) and M-CSF (also known as CSF-1), respectively 6-8. Particularly, 
Mφ2 were shown to have the unique capacity to preferentially bind and ingest early 
apoptotic cells 8. This raises the question whether the in vivo clearance of apoptotic 
cells is confined to a specialized subset of phagocytes with anti-inflammatory 
properties, such as Mφ2 5,8.
Since the results mentioned above are based on in vitro studies, a challenging task 
is to obtain insight in the physiological relevance of in vitro-polarized Mφ1 and Mφ2. 
Classically, most resident Mφ are derived from circulating bone marrow-derived 
monocytes in vivo 4. GM-CSF and M-CSF are major growth factors for Mφ 
differentiation in vivo 9. Peritoneal Mφ (pMφ) represent resident tissue Mφ of the 
peritoneal cavity, and constitute one of the few human resident Mφ subpopulations 
that are easily accessible for isolation 10.  It has been shown earlier that in mice, M-
CSF, distributed locally, plays a critical role in the differentiation of resident pMφ in 
vivo 11. In humans, the M-CSF level in the peritoneal fluid is 2.5-fold higher as 
compared to plasma, and it has been shown that the levels of M-CSF are 
correlated to pMφ numbers 12. Considering the importance of M-CSF as a major 
factor in the differentiation of resident Mφ, we undertook the current study as a 
further step to identify the in vivo counterpart of M-CSF-driven Mφ2. We found that 
human resident pMφ, freshly isolated from patients on peritoneal dialysis (PD), 
share several characteristics of Mφ2. Moreover, like Mφ2 and in contrast to Mφ1, 
resident pMφ down-regulate CD86 upon stimulation with LPS and this is 
associated with a reduction of their allogeneic T cell stimulatory capacity.  We 
hypothesize that pMφ have the potential to maintain an anti-inflammatory status in 
the peritoneal cavity.
Materials and Methods 
Patients and pMφ
pMφ were isolated from peritoneal dialysate effluents from in total fifteen PD patients at the department 
of Nephrology of the Leiden University Medical Center (the Netherlands). The underlying primary 
diseases were renal vascular disease, diabetes, hypertension, cystic nephritis and systemic lupus 
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erythematosus (SLE). All patients had been free of infection for at least 4 weeks before the collection of 
dialysate effluents. Effluents were collected from 3 to 4 h dwells. The isolation of pMφ was performed  
according the method described elsewhere 13. Briefly, peritoneal cells were collected by centrifugation 
(RPM 1500, 10 min.) from chilled dialysate effluents. After washing two times with PBS, cells were 
seeded at 1×106/ml in 6-well culture plates (Costar, Cambridge, MA) in RPMI culture medium 
(RPMI1640 containing 10% heat-inactivated FCS, 90 U/ml penicillin and 90 g/ml streptomycin). After 2 
h incubation at 37C, non-adherent cells were removed by washing with PBS. Adherent cells (pMφ) 
were harvested by cell scraper (Costar).
Generation of Mφ1 and Mφ2.
Generation of Mφ1 and Mφ2 from human peripheral blood monocytes was performed using the 
methods described previously 8. Briefly, Mφ1 and Mφ2 were generated from CD14+ monocytes in RPMI 
culture medium in the presence of 5 ng/ml GM-CSF (Leucomax, Novartis Pharma BV, Arnhem, the 
Netherlands) and 5 ng/ml M-CSF (R&D systems / ITK Diagnostics, Uithoorn, the Netherlands), 
respectively, for 6 days. 
Analysis of cell surface molecules by flow cytometry.
The following mAbs were used for flow cytometry analysis to analyze the surface molecules on different 
Mφ: anti-DC-SIGN/CD209 (AZN-D1, a gift of Dr. Y. van Kooyk, VU Medical Center, Amsterdam, the 
Netherlands), anti-CD86 (IT2.2; Pharmingen, San Diego, USA), anti-CD16 (3G8, a gift from Dr. J.G.J. 
van de Winkel, University of Utrecht, the Netherlands), and anti-CD163 (EDhu1, 14). Staining was 
visualized by PE-conjugated goat anti-mouse Ig (Dako, Glostrup, Denmark), and compared to 
appropriate isotype controls. PE-conjugated anti-CD14 (Leu-M3), and PE-conjugated anti-CD11b/Mac-1 
were purchased from BD Biosciences (San Jose, CA). Cells were analyzed using FACSCalibur and 
CellQuest software (BD Biosciences). Dead cells, identified by propidium iodide (PI) uptake, were 
excluded from analysis.
Phagocytosis assay.
Phagocytosis of early or late apoptotic cells was assessed using a protocol described previously 8. 
Briefly, fluorescently labeled with carboxyfluorescein diacetate succinamidyl ester (CFSE, Molecular 
Probes, Leiden, the Netherlands) labeled Jurkat cells were rendered into early (Annexin V+ /PI-, 
routinely  70%). and late apoptosis (Annexin V+ /PI+, routinely  95%). by irradiating them with ultra 
violet (UV)-C light (Philips TUV lamp, predominantly 254 nm) at a dose of 50 J/m2 and then cultured for 
3 and 28 hours in serum-free RPMI medium, respectively. Labeled early or late apoptotic cells (1 × 105) 
were co-cultured with pMφ in 1:1 ratio at 37C or 4C for 0.5 h in 100 l RPMI culture medium in round-
bottom glass tubes. pMφ were stained with a PE-conjugated mAb against CD11b and uptake was 
analyzed by a two-color flow cytometry. Phagocytosis of early apoptotic cells by pMφ was further 
investigated by confocal laser scanning microscopy with a LSM 510 (Carl Zeiss AG), as described 
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previously 8. pMφ were stained with mAb against CD11b or CD163 followed by Alexa red-conjugated 
goat-anti-mouse Abs (Molecular Probes) .
Allogeneic mixed lymphocyte reaction.
Responder T cells used for allogeneic mixed lymphocytes reaction (MLR) assays were isolated by 
sheep erythrocyte rosetting of mononuclear cells obtained from healthy donors. Stimulator cells, i.e. 
Mφ1, Mφ2 and pMφ, were first cultured with or without 200 ng/ml lipopolysaccharide (LPS, Salmonella 
Typhosa, Sigma-Aldrich) for 24 h.  Prior to MLR, stimulator cells were irradiated (50 Gy) and added in 
graded doses to 1.5 × 105 allogeneic T cells in 96-well round-bottom tissue culture plates in RPMI 
culture medium. Cell proliferation was quantified by incubating the cells during the last 8 h of the 6-day 
cultures with 1 µCi (37 kBq) of [methyl-3H]thymidine (NEN, Boston, MA). Results are presented as the 
mean cpm ± SD obtained from triplicate cultures.
Cytokine detection.
Mφ1, Mφ2 and pMφ (2 × 105) were stimulated with or without 200 ng/ml LPS for 24 h in 48-well-plate 
and supernatants were harvested. Cytokines were quantified in the supernatants using ELISA. The 
measurements of IL-6 and IL-10 were performed as described previously 8. The supernatants harvested 
from MLR were measured for interferon- (IFN-), according the method described before 15.
Statistical analysis.
Statistical analysis was performed by two-way ANOVA or one sample t test using GraphPad Prism 
(GraphPad software, San Diego, CA). Differences were considered statistically significant when p 
values were less than 0.05.
Results and discussion
pMφ share similar phenotype with Mφ2
The purity of pMφ isolated from the dialysate effluents of PD patients was 
determined by analysis of morphology and flow cytometry for surface markers. 
These cells showed typical morphology for monocytes /Mφ (not shown). Flow 
cytometric analysis revealed a phenotype for human Mφ, i.e. positive for CD14 and 
CD11b, but negative for DC-SIGN, a marker for DCs (Fig. 1A). The major 
contaminating cells are CD3+ T lymphocytes which represented approximately 40% 
of total peritoneal cells before removing non-adherent cells and remained 5-15% 
thereafter (data not shown). 
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Initially, to distinguish Mφ1 and Mφ2, we analyzed an array of surface makers, and 
found that CD163, a cell surface glycoprotein belonging to the group B cysteine-
Figure 1. Characterization of Mφ1, Mφ2 and pMφ. Mφ1 and Mφ2 were generated in parallel 
from the same healthy donor cultured for 6 days. pMφ were freshly isolated from dialysate 
effluents from PD patients. Surface expression (closed histograms) was determined by flow 
cytometry. Open histograms represent matched isotype controls. (A) Surface expression of 
CD14, CD11b, DC-SIGN, CD163 and CD16 (FcRIII) on Mφ1, Mφ2 and pMφ. Data are 
representative of at least 3 independent experiments using separate unrelated donors. (B) 
Confocal microscopy images show the uptake of early apoptotic cells by pMφ (see arrows). Red 
cells represent the CD11b- or CD163-positive pMφ and green ones are the CFSE-labeled 
apoptotic cells. (C) The uptake of early and late apoptoic cells was measured by flow cytometry. 
The percentage of uptake and binding (at 37C) or binding (at 4C) were calculated as 100% 




rich scavenger receptor family, is exclusively expressed by Mφ2, but not by Mφ1 
(Fig. 1A). In contrast, CD16 (Fc receptor III) is expressed by Mφ1 or subsets of 
Mφ1, but not by Mφ2. pMφ are characterized as CD163+CD16-, sharing this 
phenotype with Mφ2 (Fig. 1B). CD163 has been shown to be associated with an 
anti-inflammatory Mφ phenotype, either alternative activated Mφ or those tissue 
Mφ isolated from patients with granulomatous disease 16. Our finding that Mφ2 
express CD163 confirms the association of CD163 with anti-inflammatory activities. 
The underling pathology of the patients used for analysis was diverse, including 
renal vascular disease, diabetes, hypertension, cystic nephritis and systemic lupus 
erythematosus. Therefore we feel that it is unlikely that the Mφ2 phenotype of 
peritoneal macrophages can be attributed to a specific underlying pathology.
pMφ have high capacity for phagocytosis, endocytosis and 
macropinocytosis
An important functional characteristic of Mφ2 is that they have a higher capacity for 
antigen uptake, in particular that of early apoptotic cells, as compared to Mφ1 and 
DCs 8. Therefore we assessed the capacity for uptake of early and late apoptotic 
cells by pMφ directly after isolation from dialysate effluents. Uptake of early 
apoptotic cells was confirmed by confocal microscopy, showing that CD11b+ and 
CD163+ pMφ had ingested CFSE-labeled early apoptotic cells (Fig. 1B). 
Quantification of uptake by flow cytometry shows that pMφ were capable to bind 
early or late apoptotic cells at 4C and to engulf them at 37C (Fig 2B). Importantly, 
like Mφ2 8, pMφ exhibited a superior capacity for the binding and uptake of early 
apoptotic cells, compared with late apoptotic cells (mean fold difference: 1.87±0.17, 
p<0.01, ANOVA) (Fig 1C). Furthermore, pMφ were active in lectin-mediated uptake 
of DextranFITC and showed strong macropinocytosis-mediated uptake of luficer 
yellow (data not shown), which resembles Mφ2. Collectively, these data suggest 
that pMφ share their strong phagocytic properties with Mφ2.
pMφ produce high amount of IL-10, as do Mφ2
The anti-inflammatory Mφ2 are characterized by high IL-10 production, whereas 
the pro-inflammatory cytokines such as IL-6, TNF-α are hardly produced 7,8. We 
investigated whether freshly isolated pMφ also predominantly produce anti-
inflammatory cytokines. Mφ2, but not Mφ1, produced high amounts of IL-10 upon 
LPS stimulation (ANOVA, p<0.01) (Fig. 2A left panel). pMφ produced high amounts 
of IL-10, and LPS stimulated pMφ to produce significantly more IL-10 (mean fold 
increase: 5.19  4.67, p<0.05, one sample t test) (Fig. 2A right panel). 
Unlike the Mφ2 which produce little or no IL-6 (Fig. 2B left pannel) 8, pMφ produced 
considerable amounts of IL-6 after LPS stimulation (ANOVA, p<0.01) (Fig. 3D). 
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However, LPS was unable to induce a further significant increase in IL-6 by these 
pMφ (mean fold increase: 1.47  0.88, p>0.05) (Fig. 2B right panel). IL-6 
production by pMφ has been documented before 17 and this was dramatically 
elevated in pMφ from peritonitis patients 18. These data suggest that pMφ may 
perhaps not be as polarized as in vitro-generated Mφ2, but, nevertheless, they do 















































Figure 2. Cytokine production by pMφ after LPS stimulation. Isolated pMφ (2 × 105) were 
immediately cultured with or without LPS (200 ng/ml) for 24 h in RPMI culture medium. In parallel, 
Mφ1 and Mφ2 were stimulated by LPS in the same way. Supernatants were harvested and 
measured by ELISA for IL-10 (A) and IL-6 (B) of Mφ1 and Mφ2 and pMφ. Data shown (Mφ1 and 
Mφ2) are mean ± SD from 4 independent experiments. *, p<0.01, ANOVA.  For pMφ,  data shown 
are from 6 separate unrelated donors. Data represent the mean ± SD from duplicate cultures. 
Mφ2 and pMφ show hampered T cell stimulatory capacity 
We next investigated the expression of costimulatory molecules among these Mφ. 
Basal levels of CD80 and CD86 were comparable for all three Mφ populations. 
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LPS stimulation increased CD80 and CD86 expression on Mφ1 but failed to do so 
on Mφ2 (Fig. 3A). Instead, a significant down-regulation of CD86 was observed on 
both Mφ2 and pMφ upon LPS stimulation (Fig. 3B, p<0.01, one sample t test). In 
line with this, in an allogeneic MLR, activation of Mφ1 with LPS resulted in a 
strongly increased T cell stimulatory capacity (mean of fold increase: 1.32 ±0.35, 
p<0.01, one sample t test) (Fig. 3C). In contrast, LPS activation of both Mφ2 and 
pMφ resulted in a hampered T cell proliferation (mean of fold increase for Mφ2: 
0.90 ±0.42, p<0.01, and for pMφ: 0.88 ±0.13, p<0.01) (Fig. 3C). Measurement of 
IFN- production by activated T cells showed induction of IFN- by Mφ1 and pMφ, 
but not by Mφ2 (Fig. 3D). However, similar to T cell proliferative responses, LPS 
activation of Mφ1 increased IFN- production (mean fold increase: 2.83, p<0.01), 
whereas LPS activation of pMφ decreased the IFN- response (mean fold increase: 
0.42, p=0.012) (Fig. 3D). Taken together, Mφ2 and pMφ showed a similar pattern 
to activate allogeneic T cells, in particular with respect to the reduced T cell 
stimulatory capacity upon LPS exposure. 
The antigen presentation activities of pMφ have been studied earlier, showing that 
pMφ are competent antigen presenting cells 19,20. Our data confirm that pMφ can 
stimulate allogeneic T cell proliferation. However, our finding that LPS stimulation 
hampered the T cell stimulatory capacity and inhibited IFN- production by pMφ 
provides new insight in this type of resident Mφ.  It has been well accepted that 
both in vitro and in vivo Mφ are heterogeneous in immune activities, i.e. activating 
versus suppressing 10. Our data suggests that pMφ might be suppressor Mφ with a 
role in the maintenance of peripheral tolerance upon scavenging self antigen 
derived from for instance apoptotic cells. Indeed, the anti-inflammatory and 
immune suppressive capacities of resident Mφ were also found in other tissue Mφ, 
such as murine alveolar Mφ 21,22 and human intestinal Mφ 23. 
Concluding remarks
In conclusion, we show that human pMφ display a strong resemblance to in vitro-
generated anti-inflammatory Mφ2, thereby representing an in vivo counterpart of 
Mφ2. These CD163+ pMφ have similar capacities as Mφ2 for endocytosis, 
macropinocytosis, and a superior uptake of early apoptotic cells compared to the 
uptake of late apoptotic cells. We suggest that human resident pMφ are a subset of 
the primary phagocytes involved in the silent clearance of apoptotic cells. 
Furthermore, stimulated pMφ show a hampered capacity in allogeneic T cell 
proliferation and induce inhibition of Th1 cytokines. Thus we propose that pMφ 
have the potential to maintain an anti-inflammatory condition in the peritoneal 
cavity.































































Figure 3. T cell stimulatory capacity of Mφ1, Mφ2 and pMφ. (A) CD80 and CD86 expression 
was determined by flow cytometry on cells with (closed histograms) and without LPS stimulation 
(open histograms) for 24 h. Dashed line represents the matched isotype control. (B) Relative 
expression of CD86 on Mφ1, Mφ2 and pMφ after LPS stimulation compared to the ones without 
stimulation. Data are the mean ± SD of 3 independent experiments using 3 unrelated donors. *, 
p<0.01, one sample t test. (C) Irradiated Mφ1, Mφ2 and pMφ were added in graded dose to 1.5 
105 allogeneic T cells. T cell proliferation was quantified by incubating cells during the last 8 h of 6-
day cultures with [methyl-3H]thymidine. (D) Supernatants of MLR (Mφ:T ratio at 1:10) were 
harvested and measured by ELISA for IFN-. Dashed line indicates the detection limit for ELISA. 
Data are mean of triplicate cultures and representative of at least 4 independent experiments.
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Summary
Macrophages (M) represent dynamic cell populations that develop according to 
the nature of environmental signals. We and others have recently shown that M
can be polarized in vitro into pro-inflammatory (M1) and anti-inflammatory cells 
(M2) by the lineage-determining factors GM-CSF and M-CSF, respectively. Here 
we show that polarized M1 and M2 are not an end stage of differentiation and 
are able to reversibly undergo functional re-differentiation into anti-inflammatory 
and pro-inflammatory M. GM-CSF-driven M1 exposed to M-CSF for 6 days 
obtained a M2-like phenotype, inhibited the production of pro-inflammatory 
cytokine IL-6 and TNF-, and exhibited a reduced T cell stimulatory capacity. Vice 
versa, M2 exposed to GM-CSF exhibited a M1-like phenotype with significant 
lower production of anti-inflammatory cytokine IL-10 and a higher T cell stimulatory 
activity, and a decreased capacity for phagocytosis of early apoptotic cells. Our 
data suggest that polarized macrophages are flexible in modulating their immune 
functions upon environmental changes, i.e., steady-state versus inflammatory 
conditions. These observations are important for our understanding of the 





Macrophages (M), as one of the professional antigen presenting cells with 
phagocytic capacity, play an essential role in homeostasis as well as in innate and 
acquired immunity, and as such may be implicated in autoimmunity, inflammation, 
and immunopathology 1. In a normal adult, resident tissue M are derived from 
circulating bone marrow–derived monocytes, and are largely heterogeneous 1,2. 
Classically, granulocyte/macrophage colony-stimulating factor (GM-CSF) and 
macrophage colony-stimulating factor (M-CSF) are the primary growth factors for 
the differentiation of macrophages from monocytes 3. Among those two, M-CSF is 
the only primary M growth factor that is detectable in peripheral blood under 
steady-state conditions 4. In contrast, GM-CSF is a pro-inflammatory cytokine, 
mostly generated during inflammation and hardly detectable in circulation 5. 
Compatible with this reasoning, t has been shown that op/op mice lacking M-CSF 
develop a profound macrophage deficiency 6, whereas GM-CSF knockout mice do
not show major deficiency of M, except that the M are smaller than normal 7,8, 
confirming that M-CSF is a crucial growth factor in M differentiation. Thus under 
steady-state conditions, M-CSF could be the default cytokine in driving M
differentiation.
We and others have recently shown that M can be polarized in vitro into pro-
inflammatory (M1) and anti-inflammatory cells (M2) by GM-CSF and M-CSF 
(also termed CSF-1), respectively 9-11. Importantly, several resident tissue M, 
including alveolar, intestinal and peritoneal  M, display anti-inflammatory 
properties 12-15. It is tempting to hypothesize that under inflammatory conditions, 
anti-inflammatory M may undergo functional adaptation when GM-CSF is 
produced locally. Therefore, in the current study we investigated whether polarized 
M1 and M2 can be re-differentiated into M2- and M1-like cells when exposed 
to M-CSF and GM-CSF, respectively. We found that both M1 and M2 can 
undergo reversibly functional changes, i.e., exposure of M1 to M-CSF resulted in 
re-differentiation of these cells into M2-like cells, and vice versa.  Our data reveal
the importance of the local cytokine environment in driving M polarization and 
provide additional options for the modulation of M and therapeutic targeting.
Materials and Methods 
Generation of monocyte-derived M1 and M2.
Human mononuclear cells were isolated from buffy-coats obtained from healthy donors using Ficoll-
Hypaque (Sigma-Aldrich, St. Louis, MO), followed by anti-CD14 microbeads magnetic cell sorting, 
according to the manufacturer's instruction (Miltenybiotec/CLB, Amsterdam, the Netherlands). Two 
types of macrophages, namely M1 and M2, were generated in 6-well culture plates (Costar, 
Cambridge, MA) in RPMI culture medium (RPMI 1640 containing 10% heat-inactivated FCS, 90 U/ml 
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penicillin and 90 g/ml streptomycin) (all from Gibco/Life technologies, Breda, the Netherlands) for 6
days supplemented with 5 ng/ml GM-CSF (Leucomax, Novartis Pharma BV, Arnhem, the Netherlands)
and 5 ng/ml M-CSF (R&D systems / ITK Diagnostics, Uithoorn, the Netherlands), respectively, as 
previously described 16. In all experiments, these two types of M were generated in parallel from 
monocytes of the same donor. For re-differentiation, day-6 M1 were cultured for another 6 days in the 
presence of GM-CSF (named as M1GM) or M-CSF (named as M1M). Similarly, day-6 M2 were 
cultured for another 6 days in the presence of GM-CSF (named as M2GM) or M-CSF (named as M2M). 
Analysis of cell surface markers by flow cytometry.
Cells were harvested and washed in buffer containing 1% BSA, 1% heat-inactivated normal human 
serum, and 0.02% NaN3. The following mAbs were used for flow cytometric analysis to detect 
expression of certain surface molecules: PE-conjugated anti-CD14 (Leu-M3), mAb of anti-mannose 
receptor (MR) /CD206 (D547.3, a gift of F. Koning, LUMC, Leiden, the Netherlands) and anti-CD163 
(EDhu1, a gift of Dr. T.K. van den Berg, Department of Molecular Cell Biology and Immunology, VU 
Medical Center, Amsterdam). Expression was visualized by PE-conjugated goat anti-mouse Ig (Dako, 
Glostrup, Denmark) using appropriate isotype controls. Cells were analyzed using FACSCalibur and 
CellQuest software (BD Biosciences). Dead cells, identified by propidium iodide (PI) uptake, were 
excluded from analysis.
Detection of cytokines.
Day-6 M1 and M2 cultured with either GM-CSF or M-CSF for another 6 days were stimulated with 
200 ng/ml lipopolysaccharide (LPS, Salmonella Typhosa, Sigma-Aldrich) for 24 h and the supernatants 
were harvested for quantification of cytokine release by ELISA. In some experiments, M1 and M2
were cultured with GM-CSF or M-CSF for only one additional day and supernatants were collected. The 
measurements of IL-6, TNF- and IL-10 were performed as described before 16,17. 
Phagocytosis assay.
Early apoptosis of Jurkat T cells was induced by ultra violet (UV)-C light (Philips TUV lamp, 
predominantly 254 nm) at a dose of 50 J/m2, and followed by culture for 3 hours in serum-free RPMI 
medium. Prior to the induction of apoptosis, Jurkat cells were fluorescently labeled with 
carboxyfluorescein diacetate succinamidyl ester (CFSE, Molecular Probes, Leiden, the Netherlands), 
according to a previously described method 18. Early apoptosis was established by two-color flow 
cytometry as positive for annexin V but negative for PI. Routinely, about 60% of early apoptotic cells 
were obtained. For the phagocytosis assay, CFSE-labeled apoptotic cells (1×105) were co-cultured with 
different M at 1:1 ratio 0.5 h at 37C or 4C in 100 l RPMI culture medium in round-bottom glass 
tubes followed by staining with a PE-conjugated mAb against CD11b. The uptake was analyzed by flow 
cytometry. The percentage of CD11b-positive cells that stained positive for CFSE was used as a 
measure for the percentage of M that had ingested (37C) and/or bound (4C) apoptotic cells. 
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Allogeneic mixed lymphocyte reaction.
An allogeneic mixed lymphocyte reaction (MLR) assay was performed as described previously 15. Briefly, 
responder T cells were isolated by sheep erythrocyte rosetting of mononuclear cells that were obtained
from healthy donors. Stimulator cells, i.e. different Mφ were first irradiated (50 Gy) and then added in 
graded doses to 1.5 × 105 allogeneic T cells in 96-well round-bottom tissue culture plates in RPMI 
culture medium. T cell proliferation was quantified by incubation of the cells with 1 µCi (37 kBq) of 
[methyl-3H]thymidine (NEN, Boston, MA) during the last 8 h of the 6-day cultures. Results are presented 
as the mean cpm ± SD obtained from triplicate cultures.
Statistical analysis.
Statistical analysis was performed by one sample t test or Mann-Whitney U using GraphPad Prism 
(GraphPad software, San Diego, CA). Differences were considered statistically significant when p 
values were less than 0.05.
Results
Morphology of re-differentiated M1 and M2.
M1 and M2 were polarized in parallel from peripheral blood monocytes derived 
from the same donor by GM-CSF and M-CSF, respectively. After 6 days of
differentiation, M1 became adherent and mostly showed a “fried-egg” morphology, 
whereas M2  were less-adherent with irregular shapes as compared to M1  (Fig. 
1A). Day-6 M1 that were cultured further in GM-CSF for another 6 days (M1GM) 
retained their “fried-egg” morphology. Similarly, M2 cultured in M-CSF for 
additional 6 days (M2M) retained their M2 morphology (Fig. 1A). By exposure of 
M1 to M-CSF for 6 days, M1M did not show obvious morphological changes.
However, culturing of M2 in GM-CSF for another 6 days (M2GM) completely 
rendered them into M1-like cells, i.e. most of the cells became adherent and 
showed “fried-egg” morphology (Fig 1A).
To exclude that the observed changes were caused by differential survival of 
different M subsets during the prolonged cultures, we determined the viable cell 
counts. Counts of viable cells by exclusion of PI staining by flow cytometric 
analysis were related to total numbers of monocyte /M harvested. We observed 
that under all conditions, cell survival was between 79% and 94% (Fig 1B). 
Phenotypes of re-differentiated M1 and M2.
Polarized M1 were previously shown to express low levels of CD14 as compared 
with M2, and had no detectable expression of CD163, whereas M2 expressed 
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CD163 and high level of CD14 11,15. M1GM conserved their phenotype, i.e. 
CD14lowCD163-, whereas M1M showed significantly increased expression of CD14 
and CD163 (p=0.01, Mann-Whitney U) (Fig 2A, B).  In contrast, M2GM showed no 
major phenotypical changes as compared with M2M (Fig 2A, B). MR expression 

















































Figure 1. Morphology of Mφ1, Mφ2. Mφ1 and Mφ2 were generated in parallel from the same 
healthy donor following culture of monocytes for 6 days, and then cultured with GM-CSF (Mφ1GM or 
Mφ2GM) or M-CSF (Mφ1M or Mφ2M) for additional 6 days. (A) Pictures show the morphology of cells 
at day 6 and day 12. Images were obtained using an Axiovert 25 inverted microscope (Carl Zeiss, 
Sliedrecht, The Netherlands) with a 20 x /0.3 NA objective and Zeiss Axiovision software version 
3.1. Magnification, x 200. (B) After harvesting from day 6 or day 12 cultures, cells were stained with 
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Functional reversal in cytokine production of re-differentiated M1 and M2.
We and others have previously shown that M1 are pro-inflammatory cells that 
produce pro-inflammatory cytokines such as IL-6, IL-23 and TNF-, whereas M2 
have an anti-inflammatory profile as documented by a large production of IL-10 but 
complete absence of IL-6 and TNF- 10,11,16.  In the absence of LPS activation, non 
of the M populations produced IL-6 (Fig. 3A) or TNF- (Fig. 3B). Upon LPS 
activation, M1GM retained their capacity to produce IL-6 and TNF-. Importantly, 
under the same conditions, M1M completely lost their capacity to produce IL-6 and 
TNF-. Like M2, M2M are unable to produce IL-6 or TNF- upon LPS activation. 
Figure 2. Phenotypes of re-
differentiated Mφ1 and Mφ2. (A) 
Surface expression (closed histograms) 
of CD14, CD163 and mannose receptor 
(MR) on Mφ1GM, Mφ1M, Mφ2GM and Mφ2M
was determined by flow cytometry. Open 
histograms represent matched isotype 
controls. Data are representative of at 
least 3 independent experiments using 
separate unrelated donors. (B) Fold 
induction of expression of CD14 and 
CD163 were calculated MFI of 
expression divided by MFI of isotype 
control. *, p<0.01, Mann-Whitney U.
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However, M2GM gained the capacity to produce IL-6 and TNF- although this 









































































































































We next measured the production of IL-10. Compatible with M1 and M2 data 
10,16, M2M produced high levels of IL-10 compared to M1GM. In all five 
independent experiments, M2GM produced significantly lower levels of IL-10 as 
Figure 3. Cytokine 
production by re-
differentiated Mφ1 and 
Mφ2. Mφ1 and Mφ2 were 
cultured with GM-CSF or 
M-CSF for another 6
days. After harvesting, 
cells were stimulated with 
or without LPS (200 
ng/ml) for 24 h in 48-well 
plate. Supernatants were 
harvested and measured 
by ELISA for IL-6 (A), 
TNF- (B) and IL-10 (C).  
(D) TNF- production of 
Mφ1 and Mφ2 cultured 
with GM-CSF or M-CSF 
for additional 1 or 6 days.  
Data shown are mean ±
SD of duplicate cultures 




compared with M2GM (p<0.001, two way ANOVA).However, we found only minor 
effects when M1 were exposed to M-CSF as compared with GM-CSF (p=0.28). 
To rule out the possibility that difference in cytokine production were a direct 
consequence of the presence of GM-CSF or M-CSF, we performed kinetic 
experiments. M1 cultured with M-CSF for one day did not reverse TNF-
production, whereas an inhibition of TNF- production was observed in 6-days 
culture of M1M (Fig. 3D). Similarly, TNF- production by M2 was only induced 
when GM-CSF was given for 6 days but not 1 day (Fig. 3D). Together, these data 
suggest that upon changes of growth factors, pro-inflammatory M1 and anti-
inflammatory M2 can be re-differentiated into anti-inflammatory and pro-
inflammatory M, respectively. 
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Figure 4. Phagocytosis of early apoptotic cells by re-differentiated Mφ1 and Mφ2. CFSE-
labeled Jurkat T cells were induced into early apoptosis by treating cells with UV-C light at a dose 
of 50 J/m2 and cultured in serum-free RPMI medium for another 3 h. Early apoptotic cells (1  105
cells) were co-incubated with Mφ1GM, Mφ1M, Mφ2GM or Mφ2M at 1:1 ratio for 0.5 h at 37C or 4C. 
Prior to flow cytometric analysis, cells were stained with PE-conjugated mAb against CD11b. (A) 
shows binding of early apoptotic cells to Mφ at 4C. CD11b+CFSE+ cells were Mφ1 (B) or Mφ2 (C) 
that have taken up early apoptotic cells at 37C. (D) Quantification of uptake (at 37C) was 
calculated as 100%  ((CD11b+CFSE+)/CD11b+). Data indicate the mean  SEM of 2 independent 
experiments where duplicated cultures were performed. 
Re-differentiation of macrophage subsets
- 73 -
Phagocytosis of early apoptotic cells by re-differentiated M1 and M2.
One important functional difference between M1 and M2 is that M2 is superior 
in phagocytosis of early apoptotic cells, as compared with M1 16. We therefore 
examined whether by switching growth factors, M1 and M2 can change their 
capacity to phagocytose early apoptotic cells. As a control, co-incubation was 
performed at 4°C to measure the binding of apoptotic cells to M (Fig. 4A), 
whereas the phagocytosis assay was performed at 37°C (Fig. 4B, C) to allow 
active ingestion. M1M slightly increased their capacity to take up early apoptotic 
cells, as compared with M1GM (Fig. 4B, D). In contrast, M2GM decreased their 



























































































Figure 5. T cell 
stimulatory capacity 
of re-differentiated 
Mφ1 and Mφ2. (A) 
Irradiated Mφ1GM, 
Mφ1M, Mφ2GM or Mφ2M
were added in graded 
dose to 1.5  105
allogeneic T cells. T 
cell proliferation was 
quantified by incubating 
cells during the last 8 h 
of 6-day cultures with 
[methyl-3H]thymidine. 
Data show mean  SD 
of triplicate cultures, 




was calculated as cmp 
(Mφ:T ratio at 1:100) of  
Mφ1M against those 
cultured with Mφ1GM,  
and  Mφ2GM against 
that Mφ2M. Dashed line 
indicates the relative 
proliferation as 1. Data 
are mean  SEM of 5 
independent 
experiments where 
triplicate cultures were 
obtained. *, p<0.01, 
one sample t  test.
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T cell stimulatory capacity of re-differentiated M1 and M2.
We have recently shown that M2 exhibit a lower capacity to stimulate allogeneic T 
cell proliferation, as compared with M1 15. Therefore we investigated whether re-
differentiated M1 and M2 undergo a conversion in their T cell stimulatory 
capacity in an allogeneic mixed lymphocyte reaction. M1M showed a significantly 
reduced capacity to stimulate T cell proliferation, as compared with M1GM (Fig. 5A, 
B). Vice versa, M2GM significantly increased their capacity to stimulate T cell 
proliferation, as compared to M2M, which reached the same level of M1M to 
induce T cell proliferation (Fig. 5A, B).
Discussion
We demonstrate in the current study that polarized pro-inflammatory M1 and anti-
inflammatory M2 are able to reversibly undergo functional re-differentiation into 
anti-inflammatory and pro-inflammatory M when growth factors, i.e. GM-CSF and
M-CSF are switched, respectively. This reversal was demonstrated at the level of 
phenotype, cytokine release, phagocytic capacity and T cells stimulatory capacity. 
Our data reveal the importance of growth factors in modulating M plasticity, and 
provide important implications for therapeutic targeting of M. 
M represent heterogeneous populations 2,19,20. Mirroring the Th1/Th2 
nomenclature, many researchers refer to classically activated M by IFN- as M1 
and alternatively activated M by IL-4 and/or IL-13 as M2 20. Functional plasticity 
of M has been documented for those classically and alternatively activated M in 
human 21,22 and mice 23, showing that polarized M were able to respond to an 
“opposing” stimulus. In our study, we have used GM-CSF and M-CSF for the 
generation of M1 and M2, resulting pro-inflammatory and anti-inflammatory M
respectively, according to a recent publication of Verreck et al. 10. We realize that 
the M-CSF-driven M2 might have some resemblance with alternatively activated 
macrophages by IL-4 and IL-13 2 or type 2-activated macrophages in the mouse 24. 
However alternatively activated macrophages express low CD14 and high MR 2, 
and mouse type 2-activated macrophages secret high level of TNF-α after 
stimulation 25. These characteristics are different from human M-CSF polarized
M2, therefore we think that GM-CSF- and M-CSF-driven M are distinct from 
previously clarified macrophage subsets. Indeed, when GM-CSF-driven M1 or M-
CSF-driven M2 were stimulated with IFN- or IL-4 for 24 till 48 h, pro-inflammatory 
cytokine pattern such as  IL-6 and TNF- were not changed (data not shown). 
GM-CSF and M-CSF (or CSF-1) are two growth factors which drive M
differentiation from monocytes 3,26. From these, M-CSF is the only primary M
growth factor which is detectable in peripheral blood under steady-state conditions
4. As a pro-inflammatory cytokine, GM-CSF is hardly detectable in circulation, and 
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much of the production and action of GM-CSF occurs locally at sites of 
inflammation 5. For example, allergic patients with late-phase cutaneous reactions 
show markedly increased levels of GM-CSF mRNA in the skin 27. Enhancement of 
GM-CSF levels in circulating are observed in response to endotoxin (LPS) 28. 
Interestingly, GM-CSF can induce M-CSF production by monocytes 29,30. Therefore, 
it is likely that under inflammatory conditions, both GM-CSF and M-CSF will be
present and that this balance might impact the functional differentiation of M. Our 
data provide insights on how these two growth factors interplay and modify the 
plasticity of M for a desired immune reaction. 
One of the characteristic functions of M2 is that they preferentially recognize and 
ingest early apoptotic cells, leading to a non-inflammatory removal 16. We have 
recently suggested that most resident M such as peritoneal M are anti-
inflammatory cells that are the major phagocytes who clear early apoptotic cells 15.  
Data in the current paper showed that the pro-inflammatory M1 could acquire
higher phagocytic capacity for early apoptotic cells once exposure to M-CSF, 
supporting the role of M-CSF in modulating phagocytosis of M subsets. We 
hypothesize that in vivo recruitment of M1-like cells locally to modify them into 
M2-like cells is essential to ensure a silent clearance of apoptotic cells when 
overloaded apoptosis occurs. 
We showed that exposure of pro-inflammatory M1 to GM-CSF completely 
inhibited their production of IL-6 and TNF-, and strongly enhanced their capacity 
to stimulate T cell proliferation, whereas treatment of anti-inflammatory M2 with 
M-CSF induced their production of IL-6 and TNF-, and reduced their capacity to 
stimulate T cell proliferation. In the case of acute inflammation, the early phase is 
dominated by pro-inflammatory and/or cytotoxic cells, whereas the terminal phase 
is dominated by anti-inflammatory /tissue regenerative cells 31. Therefore, our data 
support the notion that during the due course of an inflammatory reaction, M1 that 
sustain and stimulate inflammation may convert their function to participate in the 
healing phase of the reaction 32.
Emerging evidence show that tissue resident M including alveolar 12,13,  intestinal  
14 and peritoneal Mφ 15 have anti-inflammatory properties.  In chronic diseases 
such as tumors, M have been suggested to have a dual role either in killing tumor 
or in promoting tumor survival 33. Tumor associated Mφ acquire CD163 expression 
and have anti-inflammatory properties 34-36, which potentially promotes immune 
escape of tumor cells. Our data indicated that GM-CSF treatment on Mφ2 strongly 
increased their capacity to stimulate T cell proliferation. 
In conclusion, in vitro-polarized GM-CSF-driven pro-inflammatory M1 and M-CSF-
driven pro-inflammatory M2 can undergo functional re-differentiation upon 
exposure the opposing growth factor. Such plasticity of myeloid cells has been 
observed in other experimental models including a skewing from dendritic cells 
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(DCs) to M upon exposure to interferon-gamma (IFN-) 37, or IL-6 and M-CSF 29,38, 
and a   transdifferentiation of monocyte-derived DCs into osteolcasts upon culture 
in M-CSF combined with receptor activator of nuclear factor-B ligand (RANKL) 39. 
Together with the current data, this clearly indicates that myeloid cells have a high 
plasticity and the local microenvironment will be a determining factor for the 
functional differentiation of these cells. However, it also indicates that these cells 
can adapt and functional re-differentiate when there are changes in the 
environment. These observations are important for our understanding of the
regulatory role of M and other myeloid cells in tissue homeostasis and disease 
pathogenesis.
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Summary
Apoptotic cells can be recognized and taken up by both macrophages and 
dendritic cells. Phagocytosis of apoptotic cells generally leads to active 
suppression of cytokine production by professional phagocytes. This is different 
from the response towards cells died by necrosis, which induce a pro-inflammatory 
cytokine profile. Uptake of apoptotic cells involves a large number of receptors and 
opsonins, which bind to cellular ligands exposed during the various stages of 
apoptotic cell death. Among the opsonins of apoptotic cells, complement factors, 
including C1q, and complement-activating members of the pentraxin family play an 
important role. This is indicated by in vitro phagocytosis studies and supported by 
the susceptibility to systemic autoimmunity in carriers of genetic deficiencies for 
early complement proteins. The present review summarizes the role of molecules 
of innate immunity in the handling of apoptotic cells by macrophages and dendritic 
cells. It is proposed that C1q and other opsonins prevent autoimmunity and 
maintain self-tolerance by supporting the efficient clearance of apoptotic material, 
as well as by actively modulating phagocyte function.




The innate immune system is of key importance in primary recognition of invading 
pathogens. In this respect, a large number of so-called pattern recognition 
molecules have been identified, including soluble molecules, such as complement 
factors, members of the collectin family and the pentraxin family, as well as 
membrane-bound receptors, such as members of the family of Toll-like receptors 
(TLR) and the family of C-type lectins. Pattern recognition molecules are not only 
involved in pathogen elimination but also in the clearance of apoptotic cells. The 
rapid and early removal of apoptotic cells by phagocytosis is directed by early 
changes of the apoptotic cell surface that precede the release of its intracellular 
contents. Apoptotic cells are phagocytosed by professional phagocytes, such as 
macrophages and immature dendritic cells, but also non-professional phagocytic 
neighbor cells may participate. Identification of molecules and mechanisms 
involved has revealed important parallels between innate host defense against 
pathogenic intruders and clearance of self debris, thereby shedding a new light on 
mechanisms of tolerance and immunity. 
The present review summarizes recent data on the role of pattern recognition 
molecules in the recognition and clearance of apoptotic cells, and will elaborate on 
the way these molecules might direct differential cellular responses upon apoptotic 
cell phagocytosis. 
Molecules involved in recognition and clearance of apoptotic cells
A well-recognized and early event in the apoptotic process is the loss of 
phospholipid asymmetry of the cell membrane. This leads to exposure of 
phospholipids such as phosphatidylserine (PS), phosphatidylethanolamine (PE) 
and phosphatidylcholine (PC) on the outside of the cell membrane. Exposure of 
phospholipids is a major factor in the recognition of apoptotic cells by phagocytes, 
involving membrane-bound receptors, such as the PS-receptor 2 and several 
scavenger receptors 3,4, as well as a number of soluble opsonins that can bridge 
apoptotic cells with phagocytes (Table 1 and references therein). Mice deficient for 
the membrane receptor for PS show a profound defect in the clearance of 
apoptotic cells, causing abnormal development and neonatal death 5.
Important insight into mechanisms involved in removal of apoptotic cells has been 
generated by studies in Caenorhabditis elegans (reviewed in 6,7).  In this organism, 
two genetic pathways have been defined, involving the molecules CED-1, CED-6 
and CED-7 in the first pathway, and CED-2, CED-5, CED-10 and CED-12 in the 
second pathway, which are involved in the engulfment of dying cells. A worm 
homolog of the PS receptor, psr1, appeared to be involved in the recognition of cell 
corpses, and was shown to mediate its function via interaction with the signaling 
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proteins CED-5 and CED-12 8. However, in contrast to observations in humans and 
mice, disruption of cell engulfment pathways in worms did not lead to overt 
disease. 
Table 1. Opsonins involved in bridging apoptotic cells with phagocytes
Cell surface receptors 
involved

















Via C3b receptors?a C4b Covalent binding upon activationb 10,16
Complement receptor-3



















Tyro3? d Protein S PS 27
v3 milk fat globule-
EGF-factor 8
PS, PE 28
v3 / CD36 thrombospondin-1 ?
29,30
? 2 glycoprotein PS 31,32
a. Collectin receptors and C3b receptors can mediate phagocytosis following C1q binding and 
activation of the classical complement pathway, respectively 
b. C3b and C4b can bind to complement-activating surfaces via a covalent thiol-ester linkage
c. GAS6 can also bind to other receptors related to c-Mer (Tyro-3, Axl)
d. It is not sure whether human protein S may bind to human Tyro-3 33,34
In mice and humans, impaired clearance of apoptotic cells and material derived 
from these cells is associated with the development of a systemic SLE-like 
autoimmune disease. Systemic autoimmunity was observed in mice deficient for 
serum amyloid P-component (SAP), c-Mer, C1q, C4, and IgM, all molecules 
potentially involved in such clearance processes (Table 2 and references therein). 
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Furthermore, there is a striking association between genetic deficiencies of the 
components of the classical complement pathway (C1q, C1r, C1s, C4, C2) and 
SLE in humans 35,35. This association is hierarchical, and the association of C1q 
deficiency with SLE is almost 100 %. Several groups have established that 
complement components (C1q, mannose-binding lectin (MBL), C4, C3) directly and 
indirectly interact with apoptotic cells (Table 1), as is further discussed below.
Involvement of the complement system in the opsonization and clearance of
apoptotic cells
The complement system can be activated via three different pathways, namely the 
classical pathway (CP), the alternative pathway (AP), and the lectin pathway (LP), 
which converge at the level of C3 activation (Figure 1). Whereas the LP and the AP 
primarily use a direct target recognition mechanism, the CP is mainly activated via 
binding of the initiating factor C1q to target-bound IgG or IgM antibodies. C1q is 
able to directly bind to apoptotic cells via its globular head domain 1,11, which may
induce complement activation with subsequent deposition of C4b and C3b 1. 
Moreover, C1q can also indirectly bind to apoptotic cells via several intermediates. 
Binding of IgM autoantibodies to apoptotic cells may be responsible for the major 
part of C1q binding and complement activation by apoptotic cells exposed to 
normal human serum 23,24. The pentraxin family members C-reactive protein 
(CRP), pentraxin-3 (PTX3), and SAP bind to apoptotic cells 18,20,21, which can lead 
to a direct interaction with phagocyte receptors 4, as well as to secondary C1q 
binding and complement activation 18,22.
Alternative pathway















(C1q, C1r, C1s, C4, C2)
Figure 1. The three pathways of complement activation. Each complement activation pathway 
generates a C3 convertase (C4b2a / C3bBbP), which mediate cleavage of C3, followed by 
activation of the terminal complement pathway and formation of the membrane attack complex 
(MAC).
C1q, being the recognition molecule of the CP, is functionally and structurally 
related to MBL, a major recognition molecule of the LP 36. MBL belongs to the 
family of collectins, soluble multimeric pattern recognition molecules, characterized 
by C-type lectin domains that serve for ligand recognition and collagenous domains 
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that interact with receptors. MBL can bind to apoptotic cells via its lectin domains 
12,13. However, this interaction does not lead to complement activation 13. Not only 
MBL but also L-ficolin, a member of the ficolin family that is able to activate the LP
37, is able to bind to apoptotic cells (M. Lund Jensen and P. Garred, unpublished 
observation). Other members of the collectin family include the lung surfactant 
proteins A and D (SP-A, SP-D). These molecules mediate phagocytosis of 
apoptotic cells by human and rat macrophages 14,15. A direct interaction with 
apoptotic cells has been demonstrated for SP-A 14, which was reported to be lectin 
domain-independent 14, suggesting that the mechanism involved is different from 
that used by MBL. 
The cellular receptors for C1q have been a matter of debate for a long time. Via 
peptide sequencing, the endothelial receptor for C1q, called cC1qR, was shown to 
be identical to calreticulin (CRT). CRT can not only bind to C1q, but also to MBL, 
SP-A, and SP-D 38. CRT, as well as several host-derived heat shock proteins 
(gp96, HSP70, HSP90), can bind to the 2-macroglobulin receptor CD91 39. CD91 
is a transmembrane receptor that can mediate phagocytosis, and is homologous to 
the C. elegans protein CED-1. Indeed, a complex of CD91 and CRT serves as a 
collectin receptor on the surface of macrophages and can mediate the 
phagocytosis of apoptotic cells opsonized with C1q, MBL, SP-A or SP-D 12,15. 
Furthermore, scavenger receptor A has now been reported as a second receptor 
involved in binding and internalization of CRT and gp96 40. Scavenger receptor A is 
prominently expressed not only on macrophages but also on dendritic cells and 
therefore might also be involved in the uptake of apoptotic material opsonized with 
C1q and collectins.
Opsonization in relation to the stage of cell death
Depending on the ligand on the apoptotic cell, opsonins may support clearance of 
apoptotic cells in early or later stages of the apoptotic process. Molecules that bind 
to exposed phospholipids, such as the PS receptor, several scavenger receptors, 
as well as a number of opsonins for apoptotic cells (Table 1) presumably interact 
with early apoptotic cells. For other opsonins, such as C1q, MBL, SP-A, and PTX3, 
the ligand on the apoptotic cell surface is currently unknown, but, in case of C1q 
and MBL 1,13, probably distinct from PS. Accordingly, C1q and MBL binding to 
apoptotic cells are rather late events in the cell death process: C1q binding to early 
apoptotic cells is much weaker than to late apoptotic cells and binding of MBL and
PTX3 was exclusively demonstrated to late apoptotic cells 1,13,21. Furthermore, 
SAP, an opsonin binding to PE, is able to bind to early apoptotic cells, but again 
the binding to late apoptotic cells is of much higher affinity 20. Also deposition of C4 
and C3 on apoptotic cells, as a consequence of activation of the complement 
cascade, is a late event during apoptosis 24,41. 
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C1q, MBL and PTX3 do not only bind to intact apoptotic cells, but also to 
microparticles that are released from the cell during apoptosis 1,13. Noteworthy, 
whereas we found that C1q, MBL and PTX3 always bind to a subpopulation of 
these microparticles, SAP showed strong binding to the complete population of 
microparticles collected from the supernatant of apoptotic Jurkat cells (Fig. 2), 
suggesting that this molecule, which is constitutively present in human serum in a 








Together, these data suggest that C1q, MBL and the pentraxins are primarily 
important in the clearance of apoptotic cells in later stages of the cell death 
process, after they have become leaky and/or have fallen apart in membrane-
enclosed apoptotic bodies. Therefore, in the normal clearance of early apoptotic 
cells, other clearance mechanisms may prevail, involving molecules such as the 
PS receptor. It is difficult to estimate how often late apoptotic cells do occur in vivo. 
Furthermore, in vitro and in vivo phagocytosis experiments use a mixture of early 
and late apoptotic cells, since these cells progress into late stages during handling. 
Therefore, the role of opsonins in the uptake of early apoptotic cells remains to be 
established. However, since C1q-deficient mice show impaired clearance of 
apoptotic cells 42, and since both C1q-deficient mice and humans are strongly 
susceptible to autoimmunity, the contribution of C1q to the clearance system is 
apparently important. Complement-dependent clearance mechanisms could be 
especially relevant during e.g. trauma or inflammation, resulting into an increased 
load of apoptotic material. 
Noteworthy, MBL 13 and C1q (W. Xu et al. unpublished) do not only directly bind to 
late apoptotic cells but also to cells dying via necrosis. Necrotic cells activate the 
classical complement pathway, largely via an IgM-dependent mechanism [Ciurana 
et al. submitted for publication, 41]. Also necrotic cells expose phospholipids that 
may serve as ligands for receptors and opsonins. Therefore, the clearance 
mechanisms for apoptotic cells are presumably also involved in the clearance of 
Figure 2. Binding of SAP to cell-
derived microparticles generated 
during induction of apoptosis. 
Jurkat cells were induced to apoptosis 
by treatment with 40 µM etoposide 
during 48 hours in the presence or 
absence of purified human SAP (20 
µg/ml). Microparticles were isolated 
from the culture supernatant as 
described 1 and stained for the 
binding of SAP using a monoclonal 
antibody directed against SAP, 
followed by PE-conjugated goat anti-
mouse antibodies for detection. SAP 
and mAb anti-SAP were a kind gift of 
Dr. Hack and Dr. Familian. 
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necrotic material and therefore these molecules may function as general 
scavengers of cellular debris.
Opsonization modulates the uptake of apoptotic cells
Opsonization generally increases the efficiency of the interaction between 
phagocyte and apoptotic cell and induce receptor-mediated phagocytosis, which 
accelerates the kinetics of the phagocytosis process and thus enhances the 
capacity of the phagocytic system. Most of the molecules implicated in apoptotic 
cell clearance have been shown to contribute to the uptake of apoptotic cells by 
macrophages in vitro. In vivo support for their role in clearance of self debris is in a 
number of cases available by studies in knockout mice, as presented in table 2. 
Table 2. In vivo support for a role of receptors and opsonins in the clearance of self 
debris
Molecule Phenotype of knockout mice Ref. 
C1q Systemic autoimmunity with autoantibodies and glomerulonephritis
Increased numbers of apoptotic cells in glomeruli
Delayed clearance of apoptotic cells from the peritoneal cavity
10,42
SP-D Delayed clearance of apoptotic cells from the lung 15
C4 Systemic autoimmunity with autoantibodies and glomerulonephritis
Delayed clearance of apoptotic cells from the peritoneal cavity
10,43
SAP Systemic autoimmunity with autoantibodies and glomerulonephritis
Accelerated chromatin degradation, enhanced immune response 
against chromatin
44
IgM Autoimmunity to nuclear antigens, renal IgG and complement 
deposition
45,46
c-Mer Autoimmunity to nuclear antigens, renal IgG and complement 
deposition




Accumulation of apoptotic cells in brain and lungs
Abnormal development and neonatal lethality
5
Opsonins can contribute to the clearance of apoptotic cells in a tissue-specific way. 
Mice deficient for SP-D show decreased uptake of apoptotic cells that are 
administered into the lung 15. Mice deficient for C1q and C4 show a delayed 
clearance of apoptotic cells that are injected into the peritoneal cavity 10. However, 
C1q-/- mice show a normal uptake of apoptotic cells in the lung 15. Similarly, despite 
the fact that C1q is able to bind to apoptotic keratinocytes 9, it does not seem to 
contribute to the uptake of apoptotic cells in the skin 48. C1q supports the uptake of 
apoptotic cells by macrophages but not by renal mesangial cells 49, indicating that a 
defect in clearance by mesangial cells cannot explain the increased numbers of 
apoptotic cells in glomeruli from C1q-deficient mice 42.
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The data available indicate that deficiency of apoptotic cell opsonins such as 
complement factors delays the in vivo uptake of apoptotic material by professional 
phagocytes 10. This may result into a prolonged exposure of the immune system to 
apoptotic cells and to a progression of these apoptotic cells into later stages of cell 
death, thereby increasing the risk of induction of autoimmunity. Apoptotic cells are 
a rich source of autoantigens that are known targets of autoantibodies in systemic 
autoimmune diseases such as SLE. Uptake of these autoantigens by dendritic cells 
(DC) may lead to professional presentation to naïve T cells and thereby to a loss of 
tolerance. DCs are professional antigen presenting cells that are responsible for 
induction of primary immune responses. It is now clear that DCs, depending on 
their state of maturation, also play a critical role in induction and maintenance of 
tolerance 50.  Walport and colleagues have introduced the waste disposal 
hypothesis to explain the role of C1q in the prevention of systemic autoimmunity 35. 
In this hypothesis, the main role of C1q is to promote the uptake of apoptotic debris 
by macrophages. Without C1q, the efficiency of this process is too low, leading to 
an overload of apoptotic cells which will then be taken up also by immature 
dendritic cells. 
Recent data obtained by our group indicate that C1q and MBL do not only enhance 
the uptake of apoptotic material by macrophages, but also by immature dendritic
cells (A.J. Nauta et al., submitted for publication). Therefore, it seems that these 
apoptotic cell opsonins do not make a distinction between macrophages and 
immature DCs, but allow uptake of apoptotic cells in both cell types. A potential role 
for C1q in antigen uptake by immature DCs is also strongly supported by our 
recent observation that immature DCs, but not mature DCs, are strong producers 
of C1q, even stronger than macrophages 51.
Not only C1q and MBL, but also complement activation products promote the 
uptake of apoptotic cells by DC, involving the complement receptors CR3 and CR4 
17,52. Data obtained from complement-deficient mice and humans indicate that C1q 
and complement are involved in maintenance of tolerance. Since C1q and 
complement components promote apoptotic cell uptake by both macrophages and 
immature DC, we hypothesize that these apoptotic cell opsonins have important 
immunomodulatory effects.
Opsonization may direct the cellular response to apoptotic cells
Phagocytosis of apoptotic cells by professional phagocytes not only prevents the 
release of their harmful intracellular contents, but also actively modulates 
phagocyte function 4,53. Phagocytosis of apoptotic neutrophils by human 
macrophages was shown to inhibit production of cytokines and chemokines, 
whereas production of TGF-1 was increased 54. The addition of apoptotic cells to 
macrophages also modulates cytokine production induced by TLR ligands 54,55, 
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which partially involves production of TGF-1. Apoptotic cell-induced release of 
TGF-1 in vivo was shown to require exposure of PS 56. 
With respect to dendritic cells, it has been shown that DC can engulf both apoptotic 
and necrotic cells 57-59. Similarly to macrophages, DC show suppressed cytokine 
production upon their exposure to apoptotic cells 17,59. Furthermore, antigens 
delivered to DC via apoptotic cells induced tolerance in vivo 60. However, under 
certain circumstances, exposure of DC to apoptotic cells can also induce DC 
maturation and immunity 61,62. This might be dependent on the amount of apoptotic 
cells, as well as on the presence of pro-inflammatory signals and opsonizing 
antibodies. 
At this moment, there is only little information available about how the known 
apoptotic cell opsonins interfere with the modulation of phagocytic responses by 
apoptotic cells. Apoptotic cells opsonized with CRP and complement induced 
expression of TGF- by macrophages 18. Furthermore, stimulation of the iC3b 
receptor was shown to inhibit cytokine production by DC 17. In contrast, the 
interaction of SP-A and C1q with the CD91/CRT complex on macrophages was 
recently demonstrated to be a pro-inflammatory interaction 63. However, this has 
not been studied in the context of these opsonins present on apoptotic cells, which 
could make a crucial difference. 
Contrary to the phagocytosis of apoptotic cells, which is in most cases described 
as a non-inflammatory process, phagocytosis of necrotic cells leads to DC 
maturation and macrophage activation 57,60,64. The pro-inflammatory effects of 
necrotic cells have been linked to the release of heat shock proteins 65, the 
chromosomal protein HMBG1 (high mobility group box chromosomal protein 1) 66, 
and high concentrations of uric acid 67. Strikingly, heat shock proteins and HMBG1 
were not released from cells dying by apoptosis, also not in a late stage of cell 
death. 
Heat shock proteins are now described as endogenous ligands of several 
members of the TLR family, including TLR2 and TLR4 68. Interestingly, SP-A was 
recently also shown to bind to TLR4 69. Furthermore, heat shock proteins can 
signal towards phagocytic cells via CD91 and via scavenger receptor A 39,40. This 
involves an interaction between heat shock proteins and these receptors in a 
similar way as described for calreticulin, the molecule proposed to be involved in 
the binding of C1q and collectins 12,63. Therefore, it is presently unclear whether 
and how phagocytic cells may distinguish between signals coming from heat shock 
proteins, derived from necrotic cells, and signals coming from calreticulin bound to 
C1q, present on the surface of apoptotic cells. It has been proposed that the PS 
receptor is an important "molecular switch" in this respect, determining whether or 
not the phagocytic cell should mount a pro-inflammatory or a tolerogenic response
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70. This hypothesis includes the premise that necrotic cells are somehow able to 
prevent signaling via the PS receptor. 
Concluding remarks
Opsonization of apoptotic cells is required for their safe elimination. Whereas 
appropriate opsonization will direct a rapid and anti-inflammatory clearance of 
apoptotic material by macrophages and DC, inappropriate opsonization, either in a 
quantitative or qualitative way, may lead to disturbed uptake and phagocyte 
modulation, finally resulting in a loss of self tolerance (Figure 3). 
iDC
M





















Figure 3. The role of opsonins in the handling of apoptotic cells. Appropriate opsonization of 
apoptotic cells leads to their rapid uptake by macrophages (M) or immature dendritic cells (iDC), 
and to a modulation of these phagocytic cells, leading to an anti-inflammatory response and 
maintenance of tolerance. In contrast, quantitatively or qualitatively inappropriate opsonization may 
disturb the apoptotic cell uptake, leading to a loss of tolerance, as illustrated in the lower panel. 
Dendritic cells are well recognized as the central mediators of both immunity and 
tolerance. Recent studies have revealed that also for the induction of tolerance 
immature DC need to reach a certain stage of maturation 71. In this respect we 
hypothesize that a combination of stimuli, such as opsonins, membrane-associated 
ligands, cytokines and TLR ligands, will determine whether the DC will induce 
immunity or tolerance upon encountering dying cells. Further definition of these 
signals and their effect on phagocyte responses towards apoptotic cells are 
required to understand why deficiencies in molecules involved in the handling of 
apoptotic cells are associated with systemic autoimmunity.
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Summary
Cells that undergo apoptosis or necrosis are promptly removed by phagocytes. 
Soluble opsonins such as complement can opsonize dying cells, thereby promoting 
their removal by phagocytes and modulating the immune response. However, the 
pivotal role of the complement system in the handling of dying cell has been mainly
linked to the classical pathway (via C1q) and lectin pathway (via MBL and ficolin).  
Here we report that the only known naturally occurring positive regulator of 
complement, properdin, binds predominantly to late apoptotic and necrotic cells, 
but not to early apoptotic cells. This binding is independent of C3b, and we show 
that properdin becomes a focus point for local amplification of alternative pathway 
complement activation. Properdin does not compete with C1q and MBL for binding 
to late apoptotic and necrotic cells, but exhibits a strong interaction with DNA which 
is released and exposed on these cells. Although purified properdin does not 
enhance phagocytosis, it limits the pro-inflammatory potential of necrotic cells by 
reducing TNF- release by dendritic cells and macrophages, whereas IL-10 
production remains unchanged. Our data indicate that recognition of dying cells by 
properdin is essential to drive alternative pathway complement activation and 
actively promotes an anti-inflammatory response. 




Under steady-state conditions, cells that undergo apoptosis and necrosis can be 
safely and silently eliminated by professional phagocytes, i.e. immature dendritic 
cells (DCs) and macrophages (M) 1-3. Apoptotic cells are a rich source of 
autoantigens, which are involved in the induction of self-tolerance and 
autoimmunity 4. Compelling evidence has emerged that abnormal clearance of 
apoptotic cells is associated with development of the autoimmune disease 
systemic lupus erythematosus (SLE) 5,6. 
Soluble factors from the innate immune system such as complement or pentraxins 
can opsonize apoptotic cells, thereby promoting their removal by phagocytes 6-8. In 
humans, homozygous deficiency of any of the early components of the classical 
pathway of complement activation (C1q, C1r, C1s, C4, and C2) predisposes to the 
development of SLE 9, suggesting that complement is involved in removal of dying 
cells and the immune regulation associated with this process. Complement-
mediated clearance of apoptotic cells has been well documented both in vitro 10
and in vivo 11. Nevertheless, the role of the complement system in the handling of 
dying cells has been mostly linked to the classical pathway (via C1q) and lectin 
pathway (via MBL and ficolin) 10-14. It was suggested that the main product of 
complement activation, iC3b, facilitates the removal of dead material and mediates 
peripheral tolerance 10,15,16.
The alternative pathway of complement is thought to be activated following
hydrolysis of C3, generation of C3b and formation of a positive feedback loop to 
mount a rapid local response 17. The alternative pathway was initially recognized to 
amplify complement activation triggered by classical and lectin pathways. 
Properdin, discovered in 1954 18,  is the only known naturally occurring positive 
regulator of complement activation 19. It was shown that properdin binds to C3b 
and increases the stability of the alternative pathway convertases at least 10-fold 
on target surfaces and immune complexes 20. Moreover, it has been suggested 
that properdin amplifies complement activation on a target surface through an 
organized assembly process of C3 convertase C3bBbP, accounting for a direct 
complement activation capacity of properdin 21. Properdin has long been 
recognized as one of the key players in the regulation of the complement system 18, 
nevertheless, the interaction of properdin with dying cells and the involvement of 
the alternative pathway in this process have not been investigated.
In present study, we investigated whether properdin, like C1q and MBL, contributes
to the processing of dying cells. We found that properdin binds predominantly to 
late apoptotic and necrotic cells independent of C3b, but not to early apoptotic cells, 
leading to alternative pathway-mediated complement activation. Our data suggest
that properdin is one of the important regulators involved in the handling of dying 
Properdin binds to apoptotic and necrotic cells
- 95 -
cells via: 1.) activation of alternative pathway complement; 2.) modulation of the 
immune response by antigen presenting cells by dying cells.
Material and methods
Generation of phagocytes
Generation of dendritic cells (DCs), Mφ1 and Mφ2 from human peripheral blood monocytes was 
performed using the methods described previously 22. Briefly, Mφ1 and Mφ2 were generated from 
CD14+ monocytes in RPMI culture medium (RPMI 1640 containing 10% heat-inactivated FCS, 90 U/ml 
penicillin and 90 g/ml streptomycin) (all from Gibco/Life technologies, Breda, the Netherlands) in the 
presence of 5 ng/ml GM-CSF (Leucomax, Novartis Pharma BV, Arnhem, the Netherlands) and 5 ng/ml 
M-CSF (R&D systems / ITK Diagnostics, Uithoorn, the Netherlands), respectively, for 6 days. DCs were
cultured with combination of GM-CSF and 10 ng/ml IL-4 (PeproTech, Rocky Hill, NJ). 
Induction of apoptosis and necrosis
Jurkat cells were cultured in RPMI culture medium. Early or late apoptosis was induced in Jurkat cells 
by exposure to ultra violet (UV)-C light (Philips TUV lamp, predominantly 254 nm) at a dose of 50 J/m2., 
followed by 3 or 30 hours culture in RPMI serum-free medium, respectively. Necrosis was induced by 
treating cells at 56C for 0.5 h or 5 cycles of freeze-thaw from -80C to 36C. Both apoptosis and 
necrosis were confirmed by double staining with fluorescein isothiocyanate (FITC)-labeled annexin V 
and propidium iodide (PI, VPS Diagnostics, Hoeven, the Netherlands) according to established methods 
23. Alternatively, human umbilical cord endothelial cells (HUVEC), U937 cell (monocytic cell lines), HK-2 
cell (Renal tubular epithelial cells) and Epstein-Barr virus-transformed B lymphoblastoid cell lines (EBV-
LCLs) were used for the induction of necrosis.
In some experiments, splenocytes were obtained from C3 knockout (C3-/-) 24 or C57BL/6 wild type (WT) 
mice (Harlan).  Splenocytes was rendered necrotic by incubating them at 56°C, as described above.
Phagocytosis assay
Phagocytosis of early apoptotic, late apoptotic and necrotic cells was assessed by using a protocol 
described previously 22. Briefly, prior to the induction of apoptosis or necrosis, Jurkat cells were 
fluorescently labeled with carboxyfluorescein diacetate succinamidyl ester (CFSE, Molecular Probes, 
Leiden, the Netherlands). Labeled early, late apoptotic or necrotic cells (1 × 105) were investigated 
either alone or following opsonization with normal human serum (NHS) or purified properdin. Dying cells 
were co-cultured with DCs, Mφ1 or Mφ2 in 1:1 ratio at 37C for 0.5 h in 100 l RPMI culture medium in 
round-bottom glass tubes. As a control, co-culture was performed at 4C to detect the binding of dying 
cells to phagocytes. Mφ2 were stained with a PE-conjugated mAb against CD11b and uptake was 
analyzed by a two-color flow cytometry. The percentage of CD11b-positive cells that stained positive for 
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CFSE was used as a measure for the percentage of DCs, Mφ1 or Mφ2 that ingested and/or bound 
apoptotic cells.
Isolation of properdin, C1q and MBL
Properdin was isolated from pooled human serum from volunteer donors. Serum was first precipitated 
by dialysis against 5 mM EDTA (pH 6.0). The precipitate was dissolved in Veronal-buffered saline 
(2VBS, 1.8 mM Na-5,5-diethylbarbital, 0.2 mM 5,5-diethylbarbituric acid, 145 mM NaCl), and then 
dialyzed against 0.01 M NaAc containing 2 mM EDTA (pH 6.0) and applied to a Sulphopropyl C50
column. Properdin was eluted with a linear salt gradient. Properdin-containing fractions, as determined
by ELISA, were pooled, concentrated, and subsequently applied to a Sephacryl S-300 gel filtration 
column (Pharmacia Biotech, Uppsala, Sweden). Fractions containing properdin were dialyzed against 
PBS, 2 mM EDTA and further purified using human IgG coupled to a Biogel A5 (Bio-Rad, Hercules, CA) 
to remove contaminating C1q. Purity of the properdin preparation was determined by analysis on 10% 
SDS-PAGE gel. C1q and MBL were purified from pooled human plasma obtained from healthy donors 
as described previously 25,26. 
Properdin binding assay
Binding of properdin to viable, early apoptotic, late apoptotic or necrotic cells was investigated by 
incubating cells with up to 40 μg/ml human purified properdin at 37oC for 1 h in serum-free RPMI culture 
medium. Then cells were extensively washed and incubated with a rabbit-anti-human properdin
polyclonal Ab, and detected with phycoerythrin (PE)-conjugated goat F(ab)2 anti-rabbit Ig (Southern 
Biotechnology Associates, Birmingham, US). The cells were analyzed by flow cytometry. Data from 104
events were acquired.
Binding of C1q (30 μg/ml) and MBL (10 μg/ml) were performed in the same way as properdin binding 
and detected with a monoclonal antibody (mAb) directed against C1q (mAb 2204) or MBL (clone 3E7), 
respectively. Binding was visualized with phycoerythrin (PE)-conjugated goat F(ab)2 anti-mouse Ig 
(DAKO, Glossstrup, Denmark). 
In some experiments, cells were pre-incubated with C1q or MBL, followed by incubation of properdin 
and vice versa. 
To detect the binding of properdin to DNA, double stranded DNA (dsDNA) from calf thymus (Sigma-
Aldrich), single stranded DNA (ssDNA) or human albumin (Sigma-Aldrich) were coated in PBS on 
microtiter plates overnight, and then blocked with 2%BSA before adding purified properdin. After 
washing, bound properdin was detected with Dig-labelled rabbit-anti-human properdin. Bound antibody
was developed with anti-Dig-HRP (Roche Diagnostics GmbH, Mannheim, Germany), and measured for 
absorbance at OD 451 nm. 
Serum
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C4-depleted serum (C4ds) was used as a complement source that is lacking both classical and lectin 
pathway activity, and was prepared by affinity absorption using goat anti-human C4 IgG coupled to
CNBr-activated Sepharose 4 fast flow (Amersham Bioscience Europe GmBH, Roosendaal, the 
Netherlands). C4ds was free of C4 antigen and hemolytic activity of the classical pathway could be 
resorted by purified C4.
Properdin-depleted serum (Pds) was obtained by immune absorption using Biogel-coupled monoclonal 
Ab against human properdin (a gift of Statens Serum Institut, Copenhagen, Denmark). Pds showed 
normal classical and lectin pathway activities in hemolytic assays.
Complement activation by dying cells
Activation of complement by dying cells was assessed as follows: early, late apoptotic or necrotic cells 
were pre-incubated with or without properdin at 37oC for 1 h, washed extensively and then exposed to 
different dilutions of Pds, C4ds or NHS for 0.5 h at 37oC. Deposition of C3, C4 and C5b-9 on the cell 
surfaces were detected by flow cytometry using mAbs against C3 (RFK22, 27), C4 (anti-C4-4 28) and 
C5b-9 (AE11, kindly provided by Dr. T. E. Mollnes, Nordland Central Hospital, Bodø, Norway), 
respectively. 
Detection of cytokine production by DCs, Mφ1 and Mφ2.
DCs, Mφ1 and Mφ2 (1 × 105) were incubated for 4 hours at 37oC with necrotic cells that were pre-
opsonized with or without properdin, followed by activation with 200 ng/ml LPS for another 20 h in 48-
well-plate and supernatants were harvested. The amounts of  TNF- and IL-10 in the supernatants were
quantified by ELISA, as described previously 22. 
Statistical analysis.
Statistical analysis was performed by one sample t test using GraphPad Prism (GraphPad software, 
San Diego, CA). Differences were considered statistically significant when p values were less than 0.05.
Results
Complement-mediated phagocytosis of late apoptotic and necrotic cells
Relatively pure populations of viable (90-98%), early apoptotic (40-70%), late 
apoptotic (90-100%) and necrotic cells (100%) were obtained (Fig. 1A). In 
agreement with our earlier findings, M-CSF-driven anti-inflammatory M2 
preferentially recognized and ingested early apoptotic cells, as compared to the 
ingestions of late apoptotic and necrotic cells 22 (Fig. 1B). However, opsonization of 
early apoptotic cells with normal human serum (NHS) did not enhance their uptake 
by M2 (Fig. 1B, C), while opsonization of late apoptotic and necrotic cells with 
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NHS significantly increased their uptake by M2 (p<0.01) (Fig. 1B, C). We next 
questioned whether the observed enhanced phagocytosis is associated with 
complement deposition on the dying cells. Indeed, NHS-exposed late apoptotic 
and necrotic cells, but not early apoptotic cells, displayed strong deposition of C3
by flow cytometry (Fig. 1D). Therefore we next assessed the pathways involved in 
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Figure 1. Complement-mediated phagocytosis of dying cells. (A) Early or late apoptosis was 
induced in Jurkat cells by exposure to ultra violet (UV)-C light at a dose of 50 J/m2, followed by 3 or 
30 hours culture in RPMI serum-free medium, respectively. Necrosis was induced by treating cells 
at 56C for 0.5 h. Cells were stained with annexin V and PI by flow cytometry. (B) CFSE-labeled 
early apoptotic, late apoptotic or necrotic cells (1 × 105) were first opsonized with or without normal 
human serum (NHS), then co-cultured with Mφ2 in 1:1 ratio at 37C for 0.5 h. Mφ2 were stained 
with a PE-conjugated mAb against CD11b and uptake was analyzed by a two-color flow cytometry. 
CD11b+CFSE+ cells were used as a measure for the percentage of Mφ2 that ingested apoptotic 
cells. (C) Relative phagocytosis was calculated as uptake of NHS-opsonized dying cells versus 
non-opsonized cells. Data are mean ±SEM of 3 independent experiments. *, p<0.01, one sample 
paired t test.  (D) C3 deposition (filled histogram) after NHS opsonization on early, late apoptotic 
and necrotic cells was detected by flow cytometry. Open histograms are the matched isotype 
controls.
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Properdin binds to late apoptotic and necrotic cells.
It has been shown that several serum factors bind to apoptotic cells (see review 8). 
C1q, MBL and properdin are complement factors which activate complement via 
the respective 3 pathways. We here investigated whether properdin, the only 
naturally occurring positive complement regulator, can bind directly to dying cells
that are at different stages of cell death. Similar to C1q, and MBL, properdin
showed a predominant interaction with late apoptotic cells and necrotic cells, and
no significant binding to early apoptotic or viable cells (Fig 2A, B). Properdin was 
shown to bind to both late apoptotic and necrotic cells in a dose-dependent manner 
(Fig. 2C). To rule out the possibility that the observed binding of properdin is cell 
type or method specific, different cell lines and methods for induction of necrosis 
were used. Properdin was shown to bind strongly to necrotic HUVEC, U937, HK-2 
and EBV-LCL cells, and also to Jurkat cells that were rendered necrotic by 5 cycles 
of freeze-thawing (data not shown), suggesting that binding of properdin to necrotic 
cells is a universal phenomenon and irrespective of specific cell types.
It is accepted for a long time that properdin binds to a pre-existing cluster of 
surface-bound C3b 29, thereby stabilizing the C3b-dependent C3 convertase 
C3bBb 20. However, the data presented above propose a new model for the 
binding of properdin to dying cells independent of C3b. To confirm our hypothesis, 
we investigated whether properdin could bind to necrotic splenocytes derived from 
C3 knockout (C3-/-) mice. Properdin was shown to bind strongly to necrotic 
splenocytes of C3-/-mice and the extent of binding was similar to the binding of 
properdin to necrotic cells from WT mice (Fig. 2D). Importantly, properdin did not 
bind to viable splenocytes derived from either C3-/- or WT mice (Fig. 2D).
Properdin is a focus point for amplification of alternative pathway 
complement on dying cells 
Since properdin is central in alternative pathway activation, we investigated 
whether binding of properdin to these dying cells might act as a focus point for local 
amplification of the complement system. For this purpose, we analyzed 
complement activation on necrotic cells using properdin-depleted serum (Pds). 
Cells pre-incubated with purified properdin alone, as expected, do not show C3 
and C5b-9 deposition. (Fig. 3A).  Also, in Pds, no properdin binding to necrotic cells 
was seen (not shown), however a reduced C3 deposition was observed, which is 
accompanied with a lack of deposition of the membrane attack complex C5b-9 (Fig. 
3A). Necrotic cells that had been pre-exposed to properdin, washed extensively, 
and subsequently incubated with Pds, displayed significantly increased C3 and 
C5b-9 deposition, suggesting that properdin is essential for local amplification of 


































































































Figure 2. Properdin binds to late apoptotic and necrotic cells.  (A) Viable, early apoptotic, late 
apoptotic and necrotic cells were collected and incubated with C1q, MBL or properdin. Specific 
binding (filled histogram) of C1q, MBL and properdin were detected by mAb against C1q (clone 
2204), MBL (clone 3E7) and rabbit-anti-human properdin. Open histograms are the matched 
isotype controls. (B) Fold increase of binding was calculated as the mean fluorescence intensity 
(MFI) of C1q, MBL, or properdin divided by the MFI of matched isotype controls. Data shown are 
mean ±SEM of at least 4 independent experiments. (C) Late apoptotic and necrotic cells were 
incubated with increasing concentration of properdin (up to 40 g/ml), and detected for properdin 
binding. Data shown are MFI. (D) Splenocytes from C3-/- or WT mice were first rendered necrotic 
by heating or kept viable, and measured for properdin binding. Fold increase of MFI was shown. 
Data shown are mean ±SEM of 4 independent experiments.
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To confirm that cell-bound properdin activates complement via the alternative 
pathway, we used C4-depleted serum (C4ds) as a source of complement, since C4 
is a crucial factor for both the classical and lectin pathways. Late apoptotic and 
necrotic cells were pre-incubated with properdin and washed extensively before the 
addition of increasing concentrations of C4ds. Exposure of both late apoptotic
cells (Fig. 3B) and necrotic cells (Fig. 3C) that had been pre-incubated with 
Figure 3. Properdin 
activates complement via 
alternative pathway 
(A) Necrotic cells were pre-
incubated with or without 
properdin, and then washed 
extensively before adding 
30% properdin-depleted 
serum (Pds). Data shown 
are C3 and C5b-9 deposition 
on the cells. (B) Late 
apoptotic and (C) necrotic 
cells were pre-incubated 
with or without properdin, 
and then washed 
extensively before adding 
increasing concentration of 
C4-depleted serum (C4ds). 
C5b-9 and C4 deposition on 
the cells were measured. (D) 
Necrotic cells were pre-
incubated with increasing 
concentration of properdin, 
and then washed 
extensively before adding 
30% C4ds. Cells were 
measured for C5b-9 
formation. Data are 




properdin to C4ds significantly induced the deposition of C5b-9 in a dose-
dependent manner, as compared with those without properdin, suggesting that 
properdin is the limiting factor that mediates complement activation via alternative 
pathway. As a control, we measured deposition of C4 on both late apoptotic and 
necrotic cells that had been exposed to C4ds. There was no C4 deposition neither 
on late apoptotic (Fig. 3B) nor on necrotic cells (Fig. 3C) after opsonization of C4ds, 
confirming that C4 had been effectively depleted in our C4ds preparation. When a 
fixed amount (30%) of C4ds was used, the increase of C5b-9 on the cell surface 
was dose dependently affected by the amount of properdin (Fig. 3D).
Properdin does not compete with binding of C1q and MBL to necrotic cells
We showed previously that C1q and MBL share binding ligands on apoptotic cells 
30. Since properdin was shown to bind to late apoptotic and necrotic cells in a 
similar pattern as C1q and MBL (Fig.1A), we hypothesized that properdin may bind 
to a similar structure on dying cells. Necrotic cells was pre-incubated with properdin 
and followed by increasing concentrations of C1q. A dose-dependent binding of 
C1q was observed, but properdin did not inhibit the binding of C1q to the cells (Fig. 
4A). In a reverse way, pre-incubation of necrotic cells with C1q did not decrease 
properdin binding either (Fig. 4B). Similarly, pre-incubation of necrotic cells with 
properdin did not interfere with MBL binding and vice versa (Fig. 4C). Therefore, 
our data suggest that properdin binds to a yet unknown ligand which is different 
from the one to which C1q and MBL bind. 
Properdin binds to DNA
One of the autoantigens exposed on apoptotic cells and necrotic cells is DNA 4 and 
it has been shown to be released from these cells 31. Several serum components 
have been suggested to interact with DNA, including C1q 32, MBL 33, serum 
amyloid-P component (SAP) 34, and C4b-binding protein (C4BP) 35. Based on the 
finding that properdin specifically binds to late apoptotic and necrotic cells, we 
hypothesized that properdin might bind to DNA exposed on the surface of dying 
cells. Pre-incubation of properdin with calf thymus dsDNA dose-dependently 
inhibited binding of properdin to necrotic cells (Fig. 4D), suggesting a strong 
interaction between DNA and properdin. To further confirm whether properdin 
binds to DNA, various concentrations of dsDNA and ssDNA were coated on 
microtiter plates prior to addition of properdin. Human albumin was used as a 
negative control. The binding was detected by a Dig-labelled rabbit-anti-human-
properdin Ab. Properdin showed a strong binding to both dsDNA and ssDNA at 
concentrations of 1 g/ml and higher (Fig. 4E). 
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Figure 4. Properdin does not compete for binding with C1q and MBL, but binds to DNA. (A) 
Necrotic cells were pre-incubated with properdin (40 g/ml) and followed by incubation with 
increasing concentrations of C1q (up to 60 g/ml).  C1q binding was measured. Data shown are 
mean ±SEM of 2 independent experiments. (B) Necrotic cells were pre-incubated with properdin 
(40 g/ml) or C1q (30 g/ml), then followed by incubation with C1q (10 g/ml), or properdin (20 
g/ml), respectively. C1q and properdin binding were measured by flow cytometry. (C) Competition 
between properdin and MBL (10g/ml) was investigated similar as described in (B). (D) Properdin 
was pre-incubated with increasing concentrations of calf thymus double strand DNA (dsDNA), and 
then incubated with necrotic cells. Data shown are properdin binding to the cells (MFI). (E) 
Different concentration of dsDNA and single strand DNA (ssDNA) or human albumin were coated 
on microtiter plates overnight, and then blocked with 2%BSA before adding properdin. After 
washing, plates were incubated with Dig-labelled rabbit-anti-human properdin. Signal was 
developed by anti-Dig-HRP, and measured for absorbance at OD 451 nm. 
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Purified properdin does not enhance phagocytosis of necrotic cells, but 
limits their pro-inflammatory potential.
It has been shown earlier that both C1q and MBL facilitate phagocytosis of 
apoptotic cells 12,13 prior to complement activation, accounting for a direct 
recognition of C1q and MBL by receptors on phagocytes. We here questioned 
whether properdin can enhance the removal of late apoptotic and necrotic cells by 
phagocytes. DCs, M1 and M2 generated in parallel from the same donor 
efficiently phagocytose late apoptotic cells (not shown) and necrotic cells. While 
opsonisation of necrotic cells with NHS clearly enhanced phagcytosis by M1, 
opsonisation of necrotic cells with purified properdin did not show any enhancing
activity (Fig. 5A). This was found to be true for all three types of phagocytes, 
namely DCs, M1 and M2 (Fig. 5B), suggesting that there are probably no high 



































Some opsonins from the innate immune system like C1q 13 and C4bP 36 have been 
suggested to modulate the inflammatory response. We therefore investigated
whether properdin might regulate the inflammatory response by phagocytes.
Necrotic cells were opsonized with or without properdin and then co-cultured with 
DCs, M1 and M2 in the presence of LPS. In three independent experiments, 
properdin significantly inhibited necrotic cells-induced TNF- production by DCs 
(mean ±SEM of fold induction: 0.76 ±0.14, p<0.05) and M1 (mean ±SEM: 0.59 
±0.29, p<0.05) (Fig. 6A). Since the anti-inflammatory M2 did not produce TNF-
Figure 5. Properdin alone does 
not enhance phagocytosis
CFSE-labeled necrotic cells (1 × 
105) were opsonized with or without 
properdin or 30% NHS, then co-
cultured with DC, Mφ1 and Mφ2 in 
1:1 ratio at 37C for 0.5 h. 
Phagocytes were stained with a PE-
conjugated mAb against CD11b and 
uptake was analyzed by a two-color 
flow cytometry. (A) A representative 
experiment of phagocytosis by Mφ1. 
(B) Relative phagocytosis was 
calculated as uptake of properdin-
or NHS-opsonized necrotic cells 
versus non-opsonized cells. Data 
are mean ±SEM of 4 independent 
experiments. *, p<0.01, one sample 
t test.  
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22, properdin did not show an effect (Fig. 6A). In contrast to the production of TNF-
, properdin opsonization of necrotic cells did not inhibit the anti-inflammatory 
cytokine IL-10 by both DCs (mean ±SEM: 1.16 ±0.28) and M1 (mean ±SEM: 1.0 
±0.29). Interestingly, a significant increase of IL-10 (mean ±SEM: 2.99 ±1.2, p<0.05) 
by properdin-opsonized necrotic cells on M2 was observed (Fig. 6B). Our data
therefore suggest that properdin is a regulatory factor which limits the pro-











































































































We describe here that properdin, the only known naturally occurring positive 
regulator of complement, specifically binds to late apoptotic or necrotic cells, but 
not to early apoptotic cells. Furthermore, properdin binds to DNA and down-
modulates the pro-inflammatory response induced by necrotic cells. We provide 
evidence that binding of properdin to late apoptotic cells and necrotic cells is 
independent of C3b, and serves as a focus point for the local amplification of the 
alternative pathway complement activation.
In the past, studies on complement-mediated clearance of dying cells have mainly 
focused on the classical pathway 10-12. Properdin is a positive regulator of the 
alternative pathway, which has been shown to bind to C3b and to stabilize the 





Necrotic cells were 
opsonized with or 
without properdin, 
then co-cultured with 
DCs, M1 and M2 
for 4 h followed by 
the addition of LPS 
(200 ng/ml) for 
another 20 h. 
Supernatants were 
collected for the 
measurement of 
TNF- (A) and IL-10 
(B) by DCs, M1, 
and M2. Data are 
mean ±SD of 
duplicate cultures 





labile C3b-dependent C3 convertase C3bBb 19,20. Two models have been proposed 
for the role of properdin in alternative pathway activation of complement. The first 
model suggests that properdin binds to a pre-existing clusters of surface-bound 
C3b 20. The other model suggests that properdin first binds to a surface ligand (C3b, 
C3bB or C3bBb) via one of its subunits and then promotes the assembly of further 
C3bBb at the ligand-binding sites of its adjoining subunits 21. Our data showed that 
properdin binds to late apoptotic and necrotic cells prior to C3 deposition on the 
cell surface, therefore we exclude the possibility of initial binding of properdin to the 
cells is via C3b. Evidence that binding of properdin to dying cells is independent of 
C3b was further supported by experiments showing that properdin binds strongly to 
necrotic splenocytes derived from C3-/- mice (Fig. 2D). Thus, we suggest that 
properdin binds to the cell surface of late apoptotic or necrotic cells first in the 
absence of C3 to ligands like DNA, and serves as a focus point for the local 
amplification of complement activation as soon as a C3 source is available.
Properdin is indispensable for the alternative pathway activation of complement on 
these dying cells.
We have tried to identify the ligands on late apoptotic and necrotic cells to which 
properdin binds. Our data suggest that DNA is one of the targets for properdin on 
dying cells. Indeed, DNA is massively released by apoptotic and necrotic cells 31,37, 
and has been shown to be one of the major autoantigens exposed on apoptotic cell 
surfaces 4. In pathological situations, DNA is considered as one of the 
immunologically active autoantigens 38, that can stimulate immune cells via Toll-like 
receptors 39,40. In autoimmune lupus, DNA is one of the major immunogens to 
trigger autoantibody production 41. Our finding that properdin binds strongly to DNA 
suggests a role for properdin in preventing unwanted immune activation when DNA 
is exposed on dying cells during a large scale cell death. 
Next to DNA, we also showed that properdin does not compete with the binding of 
C1q and MBL to dying cells, suggesting that properdin binds to other as yet 
unknown ligands which are different from those for C1q and MBL. It remains a 
challenging task to identify the exact additional ligands for properdin on dying cells. 
We have excluded the possibility that C3b is the ligand on dying cells, which 
initially facilitates binding of properdin. It is also not likely that phosphatidylserine 
(PS) exposed on the surface of dying cells is the ligand since properdin does not 
bind to early apoptotic cells although they do express PS. Recent data suggest that 
properdin binds to sulfatide (sulfated glycosphingolipids) 42. Whether sulfatide or 
other phospholipids are one of the key ligands on dying cells for properdin 
recognition is currently under investigation.
Interestingly, although purified properdin binds strongly to late apoptotic and 
necrotic cells, it does not lead to an enhanced phagocytosis by DCs or M. This 
might suggest that there are probably no high affinity properdin receptors on these 
phagocytes. In agreement with the earlier observations that complement-mediated 
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phagocytosis is mainly dependent on bound iC3b 10,11, we propose that a role of 
properdin in the augmentation of phagocytosis is associated with the triggering of 
alternative pathway activation of complement. 
It has been suggested that some serum factors such as C4BP 35 are able to 
dampen the pro-inflammatory potential induced by necrotic cells. The current paper
shows that properdin prevents the pro-inflammatory response of the pro-
inflammatory M1 and DCs induced by necrotic cells. Importantly, the anti-
inflammatory cytokine IL-10 is not inhibited, or even increased after opsonization of 
dying cells with properdin. This indicates that although necrotic cells are generally 
thought to release danger signals and usually uncontrolled in their dying process, 
the host is able to minimize the danger. Since we did not find any evidence of the 
presence of a potential properdin receptor on these phagocytes which could 
directly interact with properdin, it is tempting to hypothesize that down-regulation of 
pro-inflammatory potential of dying cells by properdin might be via an indirect way 
where properdin inhibits the pro-inflammatory signals exposed on dying cells. 
Therefore, we propose that properdin plays a regulatory role in the resolution of 
inflammation and maintenance of peripheral tolerance towards self antigen.
Involvement of properdin in the handling of dying cells was initially suggested by 
Kemper et al. reporting that properdin binds to early and late apoptotic cells 43. 
Here we demonstrate that properdin binds predominantly to late apoptotic and 
necrotic cells, but not to early apoptotic cells, which is consistent with the binding of 
other complement opsonins like C1q, MBL (review in 8) and Ficolin 14. Indeed, not 
only complement factors, but also natural IgM 44 and pentraxin family members 
such as SAP 45 and PTX3 46, bind to late apoptotic and necrotic cells, but hardly to 
early apoptotic cells. Therefore, it seems that most, if not all, of the serum opsonins 
engage with late apoptotic or necrotic cells. It has been accepted that removal of  
dying cells during their early stage of cell death ensures a silent process, whereas 
late apoptotic or necrotic cells might provide danger signals that activate 
phagocytes and thereby break peripheral tolerance 47-49. Therefore, soluble 
opsonins are critical to promote a safe clearance of late apoptotic and necrotic 
material. Together with our previous findings that early apoptotic cells are 
preferentially cleared by anti-inflammatory macrophages 22, we suggest that a 
hierarchy exists in the clearance mechanism of dying cells 9, where uptake of early 
apoptotic cells by local macrophages with anti-inflammatory properties is an initial 
step, whereas complement-mediated processes via all three pathways are a rather 
late event, most likely ensuring a safe clearance when an overload of apoptosis or 
defects in phagocytic capacity occur.
In conclusion, we provide evidence that properdin binds specifically to late 
apoptotic and necrotic cells independent of C3b, and acts as a focus point for the 
local amplification of alternative pathway complement activation. Furthermore, 
properdin binds to DNA and limits the pro-inflammatory response by necrotic cells. 
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We propose here that properdin plays a dual role in the handling of dying cells.
Firstly, it binds to DNA and probably other structures on late apoptotic and necrotic 
cells, potentially preventing the immune activation by the “danger” signals. 
Secondly, it is the limiting factor and focus point for local alternative pathway 
complement activation on these dying cells, thereby generating the vital opsonin 
iC3b to ensure a safe clearance.
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1.Summary of the thesis
1.1. Anti-inflammatory M may be the default phagocytes that promptly and 
silently phagocytose apoptotic cells
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a yet 
unclear pathogenesis. To date, different cytokines, soluble mediators, genetic 
factors and as well as many immune cells such as T cells, B cells, and antigen 
presenting cells (APCs), are thought to be involved in the initiation and progression
of this disease 1-6. The major targets in SLE are nuclear components (DNA,
histones, ribonucleoproteins) 1,2,7, which are mainly derived from dying cells 
(apoptotic and necrotic cells) that serve as a reservoir for such autoantigens 8,9. It 
has been suggested that defective clearance of dying cells may lead to the 
breakdown of peripheral tolerance and initiation of autoimmune SLE 3,4,10,11. In this
thesis, we have investigated the role of the innate immune system in the 
processing of dying cells and its immunological consequences.
We first discussed the current understanding of different subsets of DCs and M in 
the handling of dying cells (chapter 2). Both in vivo and in vitro data suggest that 
there are different subsets of professional phagocytes that are actively involved in 
the clearance of dying cells. Presumably, also neighboring non-professional 
phagocytes might actively participate in these processes. We hypothesized that 
under steady-state conditions, the fate of dying cells is ultimately determined by 
local conditions and the composition of the tissue. Therefore a further dissection of 
distinct functional properties of phagocyte subsets is of particular importance to 
understand how the clearance of apoptotic cells by phagocytes is regulated and 
how this may lead to induction or loss of peripheral tolerance.
To address the questions mentioned above, we generated 3 types of phagocytes, 
namely DCs, M1 and M2 in parallel from the same donor and compared their 
capacity for phagocytosis of different types of particles (chapter 3). We found that 
M-CSF-driven M2 are potent phagocytes that have the unique capacity to 
preferentially bind and ingest early apoptotic cells. This macrophage subset has 
intrinsic anti-inflammatory properties, as characterized by high IL-10 production in 
the absence of pro-inflammatory cytokines, such as IL-6 and TNF-. Importantly, 
whereas the IL-6 and TNF- production by GM-CSF-driven M1 is inhibited upon 
uptake of apoptotic cells, the anti-inflammatory status of M2 is retained during 
phagocytosis. These findings are consistent with earlier data that ingestion of 
apoptotic cells by M is a non-inflammatory process 12. We have tried to identify 
the specific receptors on M2 that are responsible for the unique recognition of 
early apoptotic cells. CD14 is one of the important molecules which recognize 
apoptotic cells 13 and it is highly expressed by M2. However, we found that CD14 
was only used by M2 for the tethering of apoptotic cells, but not for ingestion. 
Interestingly, M2 showed more potent macropinocytosis compared to DCs and 
Summary and general discussion
- 113 -
M1, and uptake of apoptotic cells was inhibited by a macropinocytosis inhibitor. 
Our studies suggest that, under steady-state conditions, IL-10-producing M2 are 
prominently involved in the clearance of early apoptotic cells.
In a normal adult, resident tissue M are derived from circulating bone marrow–
derived monocytes, and are largely heterogeneous 14,15. GM-CSF and M-CSF are 
two primary growth factors for the differentiation of macrophages from monocytes 
16. Under steady-state conditions, M-CSF is the only primary M growth factor that 
is detectable in peripheral blood 17. In contrast, GM-CSF is a pro-inflammatory 
cytokine, mostly generated during inflammation and hardly detectable in the 
circulation 18. Furthermore, knockout mice lacking M-CSF or GM-CSF confirm that 
M-CSF is a more crucial growth factor than GM-CSF in M differentiation 19-21. 
Thus under steady-state conditions, M-CSF could be the default cytokine in driving 
M differentiation. A relevant question therefore is: do in vitro polarized M1 and 
M2 exist in vivo? 
In Chapter 4, a partial answer to the question raised above was obtained. We 
isolated human peritoneal Mφ (pMφ) freshly from patients on peritoneal dialysis 
and found that pMφ have phenotypical characteristics, including CD163 surface 
expression and lack of CD16, as Mφ2 generated in vitro upon stimulation of 
monocytes with M-CSF. Furthermore, we show that like Mφ2, pMφ have the 
capacity for endocytosis and macropinocytosis, and preferentially bind and ingest 
early apoptotic cells. These cells produce large amounts of IL-10 upon stimulation 
with LPS. Moreover, upon LPS stimulation both pMφ and Mφ2 exhibit a down-
regulation of CD86, resulting in a reduced capacity of these cells to stimulate the 
proliferation of allogeneic T cells and an inhibition of Th1 cytokine release by these 
T cells. Thus, our data provide evidence for the first time that a countpart of in vitro-
polarized Mφ2 exist in vivo, and that human pMφ resemble anti-inflammatory Mφ2. 
We propose that pMφ potentially maintain an anti-inflammatory condition in the 
peritoneal cavity.
Based on the data from chapter 3 and chapter 4, we were intrigued by the 
opposing functions of polarized Mφ1 and Mφ2. Therefore, we questioned whether 
Mφ1 and Mφ2 are stable in terms of phenotype and function. In chapter 5, we 
described that Mφ1 exposed to M-CSF for an additional 6-day culture showed an
increase in expression of CD163 and CD14, an increased capacity for
phagocytosis of early apoptotic cells, and decreased capacity to stimulate T cell 
proliferation and inhibition of production of pro-inflammatory cytokines. Vice versa, 
Mφ2 exposed to GM-CSF converted these cells into Mφ1-like cells as envisioned 
by phenotype, cytokine profiles and capacity for phagocytosis and T cell stimulation. 
The data described above indicate that M1 and M2 can undergo reversible
functional changes, namely into cells with anti-inflammatory or pro-inflammatory 
properties depending on the exposure to GM-CSF or M-CSF, respectively. Our 
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data support the importance of dynamic changes in cytokine environment in driving 
M plasticity and provide moral perspectives for local therapeutic targeting.
1.2. Properdin is an important regulator in the processing of dying cells
The innate immune system has a key role in host defense against invading 
pathogens. Recent studies indicate that molecules of the innate immune system, 
including complement components and pentraxins, can also target their effect to 
self tissue such as dying cells. Chapter 6 reviewed the pivotal role of the innate 
immune system in the clearance of apoptotic cells. Among the opsonins of 
apoptotic cells, complement factors, including C1q, and complement-activating 
members of the pentraxin family play an important role. We proposed that some 
soluble factors, such as C1q, prevent autoimmunity and maintain self-tolerance by 
supporting the efficient clearance of apoptotic material, as well as by actively 
modulating phagocyte function.
Consequently, we identified that another complement component, properdin, binds 
predominantly to late apoptotic and necrotic cells, but not to early apoptotic cells
(chapter 7). Although previous studies indicated that properdin binds to pre-
existing clusters of C3b on surfaces of cells, our current data suggest that binding 
of properdin to late apoptotic and necrotic cells can occur independently of C3b. 
Furthermore, we showed that properdin serves as a focus point for local 
amplification of alternative pathway complement activation. Importantly, properdin 
exhibits a strong interaction with DNA that is released and exposed on these cells. 
It is of interest to note that properdin does not compete with C1q and MBL for 
binding to late apoptotic or necrotic cells, although C1q and MBL interact with DNA 
as well 22,23, suggesting that next to DNA, properdin may bind to other as yet 
unknown ligands. We found no direct effect of purified properdin in the 
enhancement of phagocytosis of late apoptotic or necrotic cells. However, we did 
find that opsonisation of necrotic cells by properdin limits the pro-inflammatory 
potential of necrotic cells by reducing TNF- release by DCs and M, whereas IL-
10 production is retained. Our data indicate that recognition of dying cells by 
properdin is essential to drive alternative pathway complement activation and that 
properdin actively promotes an anti-inflammatory response. The studies above 
provide additional knowledge on complement-mediated phagocytosis of dying cells, 
involving all three pathways of complement activation 24-26.
It will be a major challenge in the near future to integrate the information obtained 
in the past years and to distinguish the relative contribution of different components 
of the innate immune system to the clearance of apoptotic cells. However, also 
other parts of the immune system might have a direct or an indirect role. 
Opsonization of apoptotic cells with autoantibodies could potentially facilitate
uptake, either via Fc receptor (FcR)-mediated process or via activation of the 
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complement system. We recently observed that SLE sera contain variable amounts 
of antibodies (Abs) directed against early apoptotic, late apoptotic /necrotic cells. 
The contribution of autoantibodies to phagocytosis is still under investigation. 
Importantly, as already stated in our hypothesis, since expression of FcR is 
different among phagocytes (Xu, unpublished), the effector mechanisms will also 
strongly depend on the type of phagocyte which encounters the apoptotic cells.
2.General discussion and future directions
2.1. Is SLE a DC-driven disease?
Most experiments described in this thesis have been performed with M and M
subsets. However, several non-published experiments have been performed in 
parallel using monocyte-derived DCs. In this part of the discussion some of these 
results will be presented and these findings will be discussed in the context of 
recent developments on the involvement of DCs, or specific DC subsets, in the 
pathogenesis of SLE.
Many factors are involved in the initiation and progression of SLE, such as 
cytokines, soluble mediators, genetic factors as well as many immune cells such as 
T cells, B cells, and cytokines 1-6. Among the latter, one important cytokine is type I 
interferon (IFN-) 5,6, as in agreement with an earlier report that IFN-inducible 
genes are up-regulated in peripheral blood mononuclear cells (PBMCs) from 
patients with SLE 27. Importantly, it was suggested that IFN- mediates unabated 
differentiation of DCs, which drive the autoimmune response 28. DCs acquire 
antigens from apoptotic cells and (cross-)present these antigens to class I- or class 
II-restricted T cells 29-31. It was suggested that late apoptotic cells and necrotic cells, 
but not early apoptotic cells induce maturation of DCs, and present antigens in the 
absence of exogenous danger signals 31,32. However, others suggest that such 
maturation is due to possible contamination /infection 33. Therefore it remains 
controversial whether late apoptotic and necrotic cells one the one hand activate 
DCs, and that early apoptotic cells on the other hand are immunologically “null”. 
To address this controversy, we have tried to study how dying cells at different 
stages of cell death influence DC biology. We found that DCs loaded with early 
apoptotic, late apoptotic, or necrotic cells all inhibited pro-inflammatory cytokine 
release (Xu, unpublished). In contrast to the findings of others, we observed that 
neither late apoptotic nor necrotic cells induce DC maturation. Furthermore, We 
were unable to demonstrate that DCs loaded with early apoptotic, late apoptotic, or 
necrotic cells (cross-)present antigen to T cells. This finding is in agreement with a 
recent study showing that DCs that had captured apoptotic cells only in the 
presence, but not in the absence of TLR4 triggering by LPS, could present 
antigens to CD4 T cells 34. Thus extra danger signals provided by TLR ligands 
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could make a substantial difference in the initiation of autoimmunity by apoptotic 
cell-loaded DCs.
Plasmacytoid DCs (pDCs) are a specialized subset of DCs that produce IFN-
upon activation by virus. Although in vitro pDCs hardly ingest apoptotic cells 35, 
they do internalize immune complexes (ICs). It has been shown that apoptotic or 
necrotic cells combined with IgG from patients with SLE induce the production of 
IFN- by purified pDCs 36.  Furthermore, ICs derived from patients with SLE, upon 
intracellular delivery via CD32, were able to activate pDCs through toll like receptor 
9 (TLR9) 37. This observation was extended in another study showing that small 
nuclear RNAs within ribonucleoprotein particles activate pDCs through TLR7 38, 
suggesting a link between pDCs and autoimmmunity to autoantigens containing 
DNA or RNA. These studies have provided novel insights in the possible 
mechanisms of loss of peripheral tolerance to autoantigens in SLE. 
Nevertheless, it is too early to conclude that SLE is indeed a DC-driven disease. 
Firstly, whether late apoptotic or necrotic cells activate DCs is still a matter of 
debate. Secondly, the pivotal contribution of soluble factors in controlling danger 
singles requires further investigation. Existing data suggest that factors such as
properdin (Chapter 7) and C4 binding protein (C4BP) 39 are able to bind DNA 
exposed or released by necrotic cells, and potentially limit their pro-inflammatory 
potential. Furthermore, we recently found that complement component C1q is able 
to modulate DCs into a cell type with tolerogenic properties (Castellano et al., Eur. 
J. Immunol. in press). These findings indicate that the host itself is able to 
minimize the effect of danger signals and control inflammation by the use of 
inherent innate immune factors.
2.2. Tolerogenic M
Plasticity of pro-inflammatory M1 and anti-inflammatory M2 is a matter of
interest for further exploration. We showed in this thesis that both M1 and M2 
are not at the end stage of cell differentiation and are adaptable to changes in the 
microenvironment concerning their immunological functions (chapter 5). For 
example, exposure of pro-inflammatory M1 to M-CSF resulted in down-regulation 
of their pro-inflammatory cytokine profile such as IL-6 and TNF- production and 
up-regulation of the production of the anti-inflammatory cytokines such as IL-10. 
Similar functional changes were also reflected in their capacity to stimulate T cells. 
Next to growth factors, mediators from the innate immune system might impact 
these polarized cells to mount or tolerize an immune response. For example, 
during an infection pathogens trigger Toll-like receptors (TLRs) on myeloid cells 
and activate these cells. It is of interest to investigate how M1 and M2 respond
to TLR triggering. Our preliminary data showed that TLR2 engagement e.g. by 
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peptidoglican (PGN) is able to boost both IL-10 and IL-6 production by M1 (Fig 1) 
(Xu, unpublished). In contrast, anti-inflammatory M2 failed to produce IL-6 by 
any means of TLR triggering as indicated. Our data imply a role for TLR agonists in 







































































Figure 1. TLR activation by DCs, M1 and M2. M1 and M2 (25,000 cells) were stimulated 
with TLR agonists Lipoteichoic Acid (LTA) or peptidoglican (PGN) (1 ug/ml), or with the TLR4 
agonist LPS (200 ng/ml) for 24 hours in 48-well plates. Supernatants were harvested and 
measured for IL-10 and IL-6 production by ELISA.
Another way to activate M is via T cell cytokines such as IFN- (Th1 cytokine) or 
IL-4 (Th2 cytokine) 14. IFN- has long been considered the most powerful cytokine 
produced by Th1 cells to exert antiviral and bactericidal activities against 
pathogens 40.  However, recent data provide evidence that both DCs 41 and M 42
are able to secrete IFN- themselves. Therefore these cells are susceptible to
autocrine activation by IFN-. Furthermore, IFN- actively induces indoleamine 2,3-
dioxygenase (IDO) expression on DCs and M. IDO is an tryptophan-degrading 
enzyme involved in immune suppression and tolerance induction 43,44. In pilot 
experiments, we showed that IFN- induces IDO expression on both M1 and M2 
at RNA level, as measured by RT-PCR (Figure 2A) and real-time PCR (Figure 2B) 
(Xu, unpublished). Furthermore, we found that IFN--stimulated M1 and M2 are 
impaired in the induction of allogeneic T cell proliferation (data not shown). We are 
currently actively investigating the mechanisms that are involved in the inhibition of 
T cell proliferation by IFN-. 
Together, the plasticity of M subsets opened the door for further characterization 
of these cells, and we have obtained insight in modulating their functions towards 
cells with tolerogenic properties. It sheds some light on the potential application of 
these tolerogenic M in preventing transplant rejection. 
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Figure 2. Induction of IDO by IFN- on M1 and M2. M1 and M2 were stimulated with IFN-
for 24 h and RNA was isolated from these cells. IDO expression was measured by RT-PCR (A) or 
real-time PCR (B). 
2.3. Apoptotic cells in the regulation of immune tolerance via regulating Treg 
and TH17 cells
As discussed throughout the current thesis, apoptotic cells play an essential role in 
the regulation of immune system in terms of self-tolerance and autoimmunity. How 
such a balance is regulated is not fully understood. We showed here (Chapter 3)
that a subset of phagocytes with anti-inflammatory properties (namely Mφ2) have 
the capacity to preferentially phagocytose early apoptotic cells, resulting in a 
sustained high production of IL-10. These type of phagocytes exist also in vivo, 
namely in the peritoneal cavity and share characteristics with in vitro-polarized Mφ2 
(Chapter 4). We therefore speculate that in vivo clearance of early apoptotic cells 
is largely confined to a specialized subset of phagocytes with anti-inflammatory 
properties, leading to the maintenance of self tolerance. If overloaded early 
apoptotic cells are not cleared promptly, these cells may progress into late 
apoptosis or secondary necrosis, which consecutively activate newly recruited pro-
inflammatory phagocytes. Thus an immunogenic self-antigen presentation might 
occur which facilitates the development of autoimmune disease.
Failure of self-tolerance often leads to the development of autoimmune disease, 
whereas maintenance of self-tolerance is critically engaged with the regulatory 
CD4 T cells (Treg) 45. Treg cells produce immune suppressive cytokines such as 
IL-10 and /or TGF-β. One of major Treg cells is defined as CD4+CD25+FOXP3+ T 
cells, and can be differentiated by TGF-β 46. A breakthrough has been made 
recently by Bettelli et al. who showed that IL-6 completely inhibits the generation of 
Foxp3+Treg cells induced by TGF-β. Instead, IL-6 and TGF-β together induce the 
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differentiation of newly described pathogenic Th17 cells from naïve T cells 47. Th17 
cells are the cells producing IL-17 and have a crucial role in the induction of 
autoimmune tissue injury 48. Thus there is a reciprocal developmental pathway for 
the generation of pathogenic TH17 cells and protective Treg cells in the immune 
system depending on the cytokine balance between IL-6 and TGF-β, probably 
some other unknown cytokines. As many cells produce IL-6 and TGF-β, the main 
source of these cytokines remains to be investigated 49, and in addition it is of 
importance to study how the cytokine balance might be ticked.
As discussed earlier, IL-10 and TGF-β are the main cytokines released by 
phagocytes which have ingested (early) apoptotic cells. Therefore, we hypothesize 
that a local production of cytokines during clearance of apoptotic cells in vivo by 
anti-inflammatory phagocytes (such as Mφ2 like cells) might server as a primary 
source of IL-10 and TGF-β to initiate the differentiation of Treg cells for the 
maintenance of peripheral tolerance. It has been proposed that apoptotic cells 
induce transplant tolerance via the generation of Treg cells 50,51. The very first 
study showed infusion of apoptotic spleen cells induces TGF-β-dependent 
CD4+CD25+ T cell expansion in a bone marrow transplantation setting 52. It was 
further demonstrated in another study that administration of donor apoptotic cells 
results in indefinite graft survival mediated by generation of Treg 53. Therefore, use 
of the inhibitory effects of apoptotic cells on the anti-donor response provides a 
new approach to treat transplant rejection.
On the other hand, delayed clearance of apoptotic cells (or overload with late 
apoptotic cells /necrotic cells) might be a trigger  to shift the cytokine balance in 
terms of IL-6, TGF-β and probably other cytokines, and thereby leads to a skewing 
of differentiation of TH17 cells over Treg cells (see Figure 3). It is worthwhile to 
explore how local apoptotic cells and phagocytes regulate T cell subset 
differentiation. It should be noted that most of data mentioned above have been 
obtained in the murine system. Although it could be anticipated that a similar 
balance of Th cells exists in the human system, the exact regulation by the 
cytokine environment is not fully established.
3. Concluding remarks
Throughout this thesis, we have tried to obtain insight in how apoptotic cell 
clearance is regulated by cells or mediators from the innate immune system. We 
provide evidence that anti-inflammatory M2 fulfil the demand to efficiently clear 
early apoptotic cells in a silent manner. This probably provides an explanation on 
how apoptotic cell clearance contributes to the maintenance of self-tolerance under 
steady-state conditions. However, it remains largely unclear how the handling of 

















Figure 3. Hypothesis on apoptotic cells in the regulation of immune tolerance via regulating 
Treg and TH17 cells. We speculate that early apoptotic cells are cleared promptly and efficiently 
by resident anti-inflammatory phagocytes, leading the release of anti-inflammatory cytokines such 
as IL-10 and TGF-β. These cytokine serves the primary triggers to the differentiation of Treg cells. 
When early apoptotic cells are not cleared promptly, they may progress into late apoptosis or 
necrosis, leading to recruitment of newly elicited pro-inflammatory phagocytes to participate in the 
clearance. Consequently, pro-inflammatory cytokines such as IL-6 are release, and a cytokine 
balance is disturbed. As a result, Treg cells are inhibited by IL-6, and pathogenic TH17 cells are 
promoted by the combination of IL-6 and TGF-β.
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Systemische lupus erythematosis (SLE) is een auto-immuunziekte met reactiviteit 
tegen verschillende lichaamseigen weefsels en oplosbare moleculen. De oorzaak 
van deze ziekte is nog niet volledig opgehelderd. De betrokkenheid van zowel T en 
B cellen als antigen presenterende cellen (APC’s) is genoegzaam aangetoond. 
Ook cytokines en chemokines lijken een rol te spelen, zowel bij de inductie als 
tijdens de progressie van de ziekte. Daarnaast is duidelijk aangetoond dat de 
autoantilichamen tegen lichaamseigen componenten zoals tegen DNA, histonen, 
ribonucleaire eiwitten en tegen complement factoren van belang zijn bij deze 
ziekte. Een belangrijk aantal van deze antigenen is afkomstig van cellen die een 
geprogrammeerde celdood (apoptose) hebben ondergaan. Het is bekend dat 
dagelijks miljarden cellen in het menselijke lichaam in apoptose gaan om de 
homeostase in stand te houden. De gedachte is dat bij patiënten met SLE er een 
abnormale presentatie en/of verwerking van apoptotisch materiaal plaatsvindt 
waardoor er een abnormale immuunreactie optreedt. In dit proefschrift is vooral
aandacht besteed aan de rol die het natuurlijk immuunsysteem speelt in de wijze 
waarop cellen die dood gaan het immuunsysteem beïnvloeden.
In hoofdstuk 2 wordt de stand van zaken aangaande de verwerking van dode 
cellen door dendritische cellen (DC’s) en macrofagen (Mø’s) samengevat. Er zijn 
duidelijke aanwijzingen dat zowel in vitro als in vivo verschillende subpopulaties 
van DC’s en Mø’s bestaan die allen direct betrokken zijn bij de klaring van dode 
cellen. Verder onderzoek is nodig om na te gaan hoe en in welke mate deze 
verschillende subpopulaties van DC’s en Mø’s betrokken zijn bij het proces van 
klaring en het effect van deze dode cellen op de DC’s en Mø’s zelf.
Om deze vragen te benaderen hebben we 3 typen van fagocyten, nl. DC’s, Mø1 en 
Mø2 in parallel van dezelfde donoren vergeleken aangaande hun vermogen om 
verschillende soorten dode cellen te herkennen en te elimineren (hoofdstuk 3). 
Gevonden werd dat M-CSF-gedreven Mø2 zeer potente fagocyten zijn met een 
uniek vermogen om preferentieel vroeg apoptische cellen te binden en op te 
nemen. Deze macrofaag subpopulatie heeft intrinsiek anti-inflammatoire
eigenschappen met een hoge productie van IL-10, in de afwezigheid van de 
productie van pro-inflammatoire cytokines zoals IL-6 en TNF-α. Terwijl de 
productie van pro-inflammatoire cytokines zoals IL-6 en TNF-α door Mø1 geremd
wordt door opname van apoptische cellen, wordt de productie van het anti-
inflammatoire cytokine IL-10 door Mø2 juist versterkt. In dit proces lijkt de 
herkenning van apoptische cellen door deze macrofaag subpopulaties gereguleerd 
te worden door CD14, dat in hoge dichtheid op het oppervlak van Mø2 gevonden
wordt. Daarnaast werd gevonden dat Mø2 ook sterke macropinocytose vertoonde 
verleken met Mø1 en DC’s. Daarom denken wij dat onder normale fysiologische
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omstandigheden vooral IL-10 producerende Mø2 een prominente rol spelen in de 
klaring van apoptische cellen.
De vraag die zich voordoet is of er ook vergelijkbare subpopulaties van 
macrofagen te vinden zijn in vivo. Een eerste aanwijzing dat dat inderdaad zo is, 
werd gevonden uit onderzoek bij patiënten met een nierziekte die behandeld 
worden met peritoneaal dialyse. Deze patiënten worden frequent gespoeld met 
dialyse vloeistof die ingebracht wordt in hun peritoneum. Na de dialyseperiode 
wordt deze vloeistof geledigd uit het peritoneum. Uit de vloeistof van verschillende 
patiënten werden macrofagen geïsoleerd en onderzocht op membraan kenmerken
en functie. Gevonden werd dat peritoneaal macrofagen duidelijke karakteristieken 
gemeen hebben met Mø2 (hoofdstuk 4). De peritoneaal macrofagen produceren 
ook grote hoeveelheden IL-10 na stimulatie met LPS. Ook hebben deze cellen een 
lage expressie van CD86 en hebben ze een geringer vermogen om T cellen te 
stimuleren. Dus peritoneaal macrofagen lijken in vele opzichten op de subpopulatie 
van in vitro gegenereerd Mø2. We stellen daarom voor dat peritoneaal macrofagen 
de equivalent zijn van anti-inflammatoire Mø2, betrokken bij de handhaving van de 
normale homeostase in het peritoneum.
Wij werden geïntrigeerd door de tegenovergestelde functie van Mø1 en Mø2. 
Daarom vroegen wij ons af of deze twee subpopulaties van macrofagen een 
stabiel phenotype hebben. In hoofdstuk 5 beschrijven wij dat na generatie van 
Mø1 en Mø2 in vitro en vervolgens stimulatie met de tegenovergestelde stimulus 
resulteert in een reversibel fenotype en functie van beide typen macrofagen 
suggererend dat Mø1 en Mø2 geen eindtype fenotypes zijn en dat deze 
macrofagen onderhevig kunnen zijn aan dynamische veranderingen, mogelijk 
geïnduceerd door locale omstandigheden in het micromilieu.
Een nieuwe dimensie aan de herkenning van apoptische cellen en regulatie van 
DC’s en macrofagen werd ingegeven door onze vondst dat properdine, een 
positieve regulator van het complement systeem, bindt aan laat apoptische en 
necrotische cellen. Interessant is dat de binding van properdine aan apoptische 
cellen een gelijksoortig patroon van binding vertoont als andere moleculen van het 
natuurlijk immuunsysteem zoals MBL, C1q, CRP en SAP. De literatuurgegevens 
over de betrokkenheid van het natuurlijke immuunsysteem bij de klaring van 
apoptische cellen is uitgebreid samengevat in hoofdstuk 6. In hoofdstuk 7
beschrijven wij dat DNA mogelijk de bepalende factor is in de binding van 
properdine aan apoptische cellen en necrotische cellen. Belangrijk is de observatie 
dat properdine binding leidt tot een anti-inflammatoire reactie van macrofagen en 
DC’s op herkenning van apoptisch materiaal. Deze bevindingen samen met onze 
observaties over de differentiële effecten van subpopulaties van fagocyten 
suggereren dat de herkenning en de daaropvolgende immuunrespons een delicate 
balans vormen tussen de verschillende spelers in dit veld. Daarom zal bij mogelijke 
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therapeutische interventies een tussenweg gevonden moeten worden om bij ziekte 
de balans op de juiste wijze te corrigeren, zonder dat de herstelde homeostase 
weer verstoord wordt.
Uit het onderzoek beschreven in dit proefschrift is het ook duidelijk geworden dat 
de initiële hypothese dat een beperkt aantal spelers in het immunologische veld 
van belang zijn voor de klaring van dood materiaal te simpel is en dat systematisch 
onderzoek van belang is om ons inzicht in dit complexe proces verder te 
verscherpen. De uitdaging voor de komende tijd is om deze en nog te verkrijgen 
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